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ABSTRACT
Quantifying Protein Quality to Understand
Protein Homeostasis
Hsien-Jung Lavender Lin
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Proteins are the center of all biochemical reactions in living organisms. Proteins need to be
present at the right time, in the right place, with the correct concentration and have the right shape
to carry their designated function. Protein homeostasis is when all proteins in the proteome are in
functional balance, and such balance is maintained by synthesis, folding, and degradation
machinery. When protein homeostasis is lost, organisms start to age and develop diseases. To truly
unveil disease mechanisms and provide more efficient means for treatment and prevention, we
need a holistic understanding of the mechanism of protein homeostasis.
Currently, most biomarker studies focus on the quantity aspect of the proteome. The quality
aspect has been neglected because of the difficulties in measuring quality in vivo with cellular
context retained. This work first proposes a kinetic model of protein homeostasis, which can
provide a holistic view, including both quantity and quality aspects, as well as monitor the complex
protein interactions. Using mass spectrometry, the model quantifies the quality of proteome by
linking the concentration of protein, mRNA, and the rate protein synthesis, folding, unfolding,
misfolding, refolding, degradation of the correctly folded protein, and degradation of protein
aggregation.
We then applied the ideas within the kinetic model of protein homeostasis to study several
proteins in human blood serum. We reviewed the current known mechanism of transthyretin
mediated amyloidosis and proposed a study approach that can measure the quality difference
between different transthyretin’s mutation stages, as well as monitor if the transthyretin
amyloidosis has been developed at the early stage. We also used mass-spectrometry to quantify
the surface accessibility differences in human serum albumin (HSA) between patients with and
without rheumatoid arthritis (RA). We found certain residues are less reactive in the RA group,
indicating a structural change in HSA. Such structural changes, possibly caused by ligand binding,
stabilized HSA and explained the heat denature curve shift we observed. In the end, we introduced
a novel assay, Iodination Protein Stability Assay (IPSA). IPSA is used to quantify protein quality
by measuring protein folding stability. We applied IPSA to human serum, and it is the first in situ
study, to our best knowledge, that measure the protein folding stability of proteins from human
serum. We confirmed that IPSA is sensitive to measuring the differences in protein folding stability
between transferrin’s different iron-binding states. Together, this dissertation conveys the
importance of adding quality aspects to current quantity-focused research in curing diseases and
improving the quality of human life.

Keywords: protein homeostasis, proteomics, mass spectrometry, protein quality, protein
misfolding, protein aggregation, protein folding stability, human serum, transthyretin, cardiac
amyloidosis, serum albumin, rheumatoid arthritis, protein footprinting, transferrin
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CHAPTER 1: INTRODUCTION

1.1 Cell Functionality and Protein Homeostasis
Scientists have been amazed by the complex tasks that living organisms can perform. We
ask questions about how lives start, grow, age, and die. We are curious how organisms deal with
environmental challenges, then heal, learn, and maybe even evolve. Humans might be the most
intelligent animal on the planet. However, we are still inspired by the “superpowers” of the animals
and plants surrounding us, like the longevity (and cancer-free status) of whales, the energy
production of plants, or the night vision of bats. We hope to solve the mechanism behind those
superpowers, so we can adapt to live longer and better. As biochemists, we are interested in the
mechanism at the molecular level. We learn how all the biomolecules: nucleic acids (DNA),
proteins, and metabolites (lipids, carbohydrates, metal) interact to maintain our lives.
Among all the biomolecules, proteins are at the center of sustaining life. These protein
molecules are created by our bodies and should not be confused with the proteins we consume in
the diet. Dietary proteins are broken apart to supply amino acids required for life. The proteins
referred to here are polypeptide chains made in our bodies from 20 different types of amino acids.
Generally, proteins are 50 to 1000 amino acid residues in length1 and are folded into a specific 3D
shape. Proteins act as enzymes to catalyze biochemical reactions2. For example, the energy of
living organisms, ATP, is converted from ADP. The conversion happens because the enzyme
pyruvate kinase in glycolysis moves the phosphoryl group from phosphoenolpyruvate3. Proteins
also provide structural support. For example, titin, the largest human protein (38,138 residues in
length and 4.2MDa in mass), is a molecular spring in muscle cell4. Proteins also transport
metabolites (e.g., hemoglobin transports oxygen5, 6), and can be hormones passing down signals
1

between systems. For example, insulin, a small 51 AA protein, regulates blood glucose level7. All
tasks for living organisms, from basic survival like breathing, feeding, and defending to high-level
thinking like communication and creation, required proteins to function accurately.
These proteins must be present at the right time, in the right place, with the correct
concentration, and have the right shape. In other words, protein homeostasis (proteostasis), the
stable equilibrium state of all proteins, is critical for the health of living organisms. As of June
2022, searching “proteostasis” in google scholar results in only 3480 entries dated before 2012,
13,400 entries dated between 2013 to 2017, and 18,900 entries dated between 2018 and 2022. The
statistic shows increased attention to protein homeostasis over the last decade.

Figure 1 The loss of protein homeostasis results in diseases

Protein homeostasis control requires a series of steps. Dysfunction of any of these steps
can lead to disease (Figure 1). The decline of protein homeostasis can be observed through an
2

increase in oxidative damage8, changes in post-translational modification9, or modified protein
turnover rates10. In fact, it has been suggested that the loss of protein homostasis is the cause of
aging11, one of the most concerning health and social issue nowadays. Scientific and medical
advancements have extended the human lifespan for about 30 years in the last century. As a result,
age-related diseases, such as neurodegenerative disorders (Alzheimer’s disease and Parkinson’s
disease), coronary heart disease, type 2 diabetes, and cancer, also have become more common12.
Age-related diseases significantly decrease the quality of life in the elderly. Not only is it a
challenge for the patients, but the time and monetary support often burden the family and even
healthcare providers. Aging is the primary risk factor for these diseases, but unlike other risk
factors, aging is still an unpreventable and irreversible biological process. Collective efforts have
been put into aging and longevity studies in attempt to slow down the negative outcome of aging
or even reverse it. The extension in life span is great, but after all, our goal is to have an
independent, well-living, and well-contributed life, not just delaying death. The key to that
(conquering the negative effect of aging) is in unveiling the mechanism of protein homeostasis.
In this chapter, we summarize each protein homeostasis control step, examine current
methods used to study each of these steps, and propose a simple kinetic protein homeostasis model
that can be used to test for regulation of all proteins in a proteomics experiment. The proposed
kinetic model incorporates measurements of critical steps in protein homeostasis control
(synthesis, folding, and degradation) to provide a holistic understanding of how protein
homeostasis is modified under different conditions. The ultimate goal is to build a better tool to
help unveil the mechanism of protein homeostasis maintenance. The unveiled mechanism will lead
to a better understanding of aging and age-related diseases and thus prompt earlier diagnosis and
more efficient treatment approaches.
3

1.2 Protein Homeostasis Controlling Steps

Figure 2Protein Homeostasis controlling steps

To understand how living organisms maintain protein homeostasis, we need first to learn
the life cycle of a protein: synthesis, folding, and degradation (Figure 2). Proteins are synthesized
from genetic material DNA. The exons in the DNA, which code for different proteins, are translated
into mRNA upon activation. The mRNA is then transcribed by the ribosome, and with the assistance
of charged tRNAs, which carry free amino acids, polypeptide chains are synthesized. In order to
form a functional protein, the polypeptide chain needs to be folded into a specific 3D structure.
Once folded, proteins bind ligands (other proteins or metabolites) to facilitate biochemical reactions.
There are also housekeeping proteins that correct the misfolded protein species to ensure their
proper function. At the end of a protein’s life, it is tagged for degradation. The protein is broken
down into amino acids to be utilized for another protein’s synthesis. The protein homeostasis is
lost when there is even just one problem in any stage of a given protein’s life cycle.
4

1.2.1 Quantity Control: Synthesis and Degradation

Figure 3 Synthesis and Degradation Rate effect Protein Concentration

Irregular quantities of proteins in a living organism are probably the first sign of poor
protein homeostasis. Currently, most diagnosis and disease mechanism studies heavily focus on
protein biomarkers' concentration differences. While some diseases are linked to excess protein,
some are linked to lack of protein. For example, BCL-2 is frequently overexpressed in cancer
cells13 and the lack of insulin can lead to diabetes14, 15. In fact, concentration bias is a secondary
indication of dysfunction, and such bias can be broken down to the change in protein synthesis
rate or degradation rate (Figure 3A). Excess proteins can reflect either increased synthesis rate or
decreased degradation rate (Figure3B,3E). Vice versa, the lack of proteins can reflect either
decreased synthesis rate or increased degradation rate (Figure 3C,3F). Even if the protein
concentration remains the same, synthesis and degradation rates might have been modified
5

together (Figure 3D). Irregulated protein synthesis can happen at the translation or transcription,
through changes in the stability of mRNA16 or the quality of ribosome 17 (Table 1). On the other
hand, irregulated protein degradation can happen because of the malfunction of the degradations
mechanism (e.g., ubiquitin-proteasome system (UPS) and autophagy) or because of increases in
misfolded protein or protein aggregation (Table 1). The ability to study protein concentration bias
between different diseases status has accelerated the understanding of disease mechanisms and
thus prompted many effective prevention and treatment approaches.

Table 1 Example of irregular Protein Synthesis and Degradation

Synthesis

Increased

example

Decreased

Overexpressed
gene

Oncogene for cancer,
e.g., HER218, EGFR19,
AKT220.

Downregulated
gene

Overactive
protein synthesis
activity

Evaluated global
protein synthesis and
ribosome biogenesis
for Hutchinson-Gilford
progeria syndrome24

Underactive
protein
synthesis activity

Increased
misfolded protein

CFTR protein for
Cystic fibrosis26;
Hemoglobin subunit
beta chain for sickle
cell diseases27

Accumulation of
protein
aggregation

Tau protein for
Alzheimer’s diseases;
Transthyretin for
cardiac amyloidosis28;

Overactive autophagy
links to premature
suture ossification29

Underactive
degradation
activity

Downregulation of
ubiquitin-proteasome
system (UPS) inhibits
cancers30-32;
UPS activity declined
in neurodegenerative
diseases33, 34

Degradation
Overactive
degradation
activity

6

example
Tumor suppressor for
cancer, e.g., PTEN21, 22,
p5318;
Insulin for diabetes23;
Defective Ribosomes
defection results in
anemia and bone
marrow failure in
childhood, e.g.,
Diamond-blackfan
anemia25

1.2.2 Quality Control: Folding
In addition to quantity, quality control is also essential in maintaining protein homeostasis.
The quality of a given protein should be evaluated by the ability to carry out its designated function.
In order to perform, proteins need to be in the correct structure so they can bind to metabolites or
other protein ligands. The blueprint of proteins’ 3D structure is embedded in their amino acid
sequence. The physical property (polarity, hydrophobicity, charge, and size) of each amino acid
affects their interaction with each other. Protein folding is a spontaneous, free energy-driven (Gfolding ) process35 (Figure 4). Intramolecular hydrogen bonds form between amino acids and fold
into secondary structures (alpha helix, beta sheet, or loop) after synthesis. Then, multiple
secondary structures together form the tertiary structure, which defines the structure of a functional
protein. The structure of a native protein often requires the least amount of free energy to stabilize
it. This stable native protein is then available to interact with ligands and do its job. That being
said, the key to maintaining the quality of proteins is to preserve their native structure. The native
structure can be affected during translation (mutation) or post-translationally (misfolding and
aggregation).

Figure 4-Protein Folding Funnel
7

1.2.2.1 Mutation
It is well known that gene mutations can lead to severe diseases and health concerns. It is, in fact,
the change of the protein’s structure coming from gene mutation causing the problem. As mentioned
above, the protein’s structural blueprint is encoded in the protein sequence, and the protein sequence
is encoded in the DNA. As a result, even a single nucleic acid mutation can make a difference in a
protein’s structure. It doesn’t take a dramatic change in protein structure. Even one small change can
massively affect a protein’s stability, the capability to interact with ligands, and perform its designated
duties. Many genetic disorders are due to mutation in the protein sequence, and such mutation results

Figure 5-Protein Structure Changes due to Mutation
It demonstrates that mutation results in protein structural changes. (A) Transthyretin is a
monomer, and the tetramer is the functional form. Panel A hypothesizes the mutation of the
monomer opens the monomer into a bowl shape, and the misfolded monomer associated with each
other forms amyloid. (B)Sickle cell disease results from one single mutation in the hemoglobin
beta chain (HBB). The blue chain is normal HBB (PDB: 1A0U), the gray chain is mutated HBB
(HBS) (PDB: 5E83), and the orange is the mutation site. This one mutation on HBB dramatically
changes its structure when the hemoglobin tetramer form. As shown in panel B, there is a channel
at the center of normal hemoglobin, but that channel is disappeared in misfolded hemoglobin (the
light blue and green part on the protein is used to reference the protein position).

8

in structural and thus defects in functionality. For example, mutated Huntingtin protein (HTT), which
has much more glutamine repeats, prompts HTT aggregates in the brain and results in Huntington’s
disease36,

37

; The amino acid type (cysteine or arginine) at uniport position 130 and 176 of

apolipoprotein E (APOE gene) differentiate APOE2/3/4, which has different risk factors for
developing Alzheimer’s diseases38-40; There are 150 known human transthyretin (TTHY) site
mutations, which increase the risk of developing TTHY amyloidosis later in life28(Figure 5A);
Mutation at the uniport position 7 of hemoglobin subunit beta chain (HBB) changes glutamate to
valine. This mutation forms a long fiber and results in sickle-shaped red blood cells (Figure 5B),
which is the cause of sickle cell disease41, 42; Breast cancer type 1 susceptibility protein (BRCA1)
mutation is known to increase the risk of developing breast cancer43. One of the many BRCA1
mutations, M1775R (methionine to arginine) at the C-terminal domain of BRCA1 (BRCT), alters the
protein surface and leads to the destabilization of BRCA1 and the defection of DNA repair function4345

. These examples illustrate how mutations in DNA sequence lead to mutations in the protein

sequence. These changes in amino acid chemistry result in protein structural changes, affects a
protein’s stability or its interaction with ligands, and in the end, diseases develop.
1.2.2.2 Misfolding and Aggregation
The folding funnel model says the native protein falls through different energy stages and
settles at the bottom, where the free energy is minimal. However, as shown in Figure 3, the funnel
isn’t smooth. Sometimes proteins get stuck in those humps and bumps midway and cannot arrive
at the bottom. Note that protein folding is a constant equilibrium process between unfolded and
native folded stages. In a given moment, some percentage of the protein population is folded
natively while the other is unfolded. A protein not at its native structure is a misfolded protein.
For example, misfolding can happen (1) right after synthesis, as a result of mutation of the protein

9

sequence and translational errors, or (2) after the protein has arrived at its native folded stage,
which is the result of abnormal protein modifications, environmental stress (temperature, pH, or
oxidation), or incomplete complex formations46.
The protein homeostasis network (PN) comprises proteins that maintain the protein
homeostasis: synthesis, folding and degradation47, 48. Molecular chaperones are the center of
maintaining proteins’ structural integrity and correct confirmation.49-51. Chaperones are involved
in (1) shielding newly synthesis nascent peptides (e.g., Nascent-polypeptide-associated complex
(NAC52) and prefoldin53, 54) from the environment and intermolecular interaction, and thus prevent
aggregation53, 55-57; (2) folding complex protein in a timely manner53 (e.g., Hsp60/ chaperonins/
CCT complex assist protein folding in a larger cylinder like complex57); (3)refolding proteins
which have lost their correct confirmation (e.g., Hsp9056); (4) disaggregate protein aggregation57
(e.g., Hsp7058,

59

, Hsp10058). It is incredible that cells have such detailed mechanisms in

responding to all levels of folding errors, ensuring proteins’ optimal performance.
The misfolded protein is unstable. Thus is usually quickly degraded or corrected by the
maintenance mechanism before interacting with other misfolded proteins and forming
aggregations, which are ultra-stable and difficult to be degraded60. The accumulated protein
aggregation is often observed in neurodegenerative diseases (Alzheimer’s disease, Parkinson’s
disease, and Huntington’s disease). Besides neurodegenerative diseases, type II diabetes, certain
heart diseases, and cancers are also linked to cellular toxicity due to protein aggregation49. These
diseases are more profound in the senior population, probably due to gradually decreased protein
homeostasis network performance from aging (Figure 1).
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1.2.3 The complexity of the Protein Homeostasis Network (PN)
It takes multiple proteins from the PN working together to maintain a given protein’s
structural integrity. Then, it takes multiple functional proteins to make a biochemical reaction
happen. Any biochemical reaction comes from a series of interactions between multiple proteins
and metabolites. Metabolism is the result of metabolites being passed down to different proteins
and converted to energy. Metabolites are signaling molecules that bind protein receptors and
trigger signal transduction (e.g., estrogen61). Likewise, a protein interacts with another protein to
pass down the signal or binds DNA to initiate transcription. Each biochemical reaction is a cell
signal transduction pathway. On one hand, a protein that is involved in one pathway can also be
involved in multiple other pathways (function). On the other hand, multiple different proteins can
trigger a pathway (biochemical action).
For example, p53 affects multiple downstream pathways, including promoting apoptosis,
mitochondrial metabolism, and DNA repair. p53 also regulates glycolytic flux, oxidative stress,
immune response, and cell proliferation62, 63. In contrast, apoptosis, the programmed cell death,
can be regulated by different proteins includes: caspases, p53, amyloid-B peptide, and Bcl-2
family64. The mutual protein and metabolites between different pathways are the nodes that
connect different pathways and form a complex network. As a result, the activity of only one node
can create a ripple effect, where thousands of activities happen in the cell simultaneously. While
thorough research of the mechanism of a particular pathway has been providing critical insights
for disease prevention and treatment development, we need to remember that we are only see a
fraction of the entire protein network. In order to truly understand protein homeostasis control,
unveil diseases mechanism and improve treatment efficacy, we need to have a holistic view of all
the cross effects in the cell.
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1.3 Current Proteomic Techniques in Studying Protein Homeostasis Control
Thanks to the advancement in genomic sequencing and mass spectrometry (MS), as well
as improved bioinformatic and computational power, we can now identify and quantify thousands
of proteins from cell or tissue homogenate in one single experiment65. Studying a protein in the
context of the entire proteome allows us to understand the protein’s behavior under physiological
conditions while the protein’s interactors are in place. Since protein homeostasis requires synthesis,
folding, and degradation pathways working harmoniously, a holistic proteomic measurement of
all proteins together would be our best chance to understand the cellular activities necessary to
maintain protein homeostasis comprehensively. This section discusses current MS-based
techniques for protein quantity and quality studies.

1.3.1 Measurements of Protein Quantity
1.3.1.1 Concentration
Investigating biomolecule concentration biases between conditions is probably the first
puzzle biochemists try to solve when it comes to diseases. We want to find specific targets to make
early diagnoses and propose treatments centered around a particular measurement. Western blot66
and enzyme-linked immunosorbent assay (ELISA)67 are the most common techniques for
quantifying specific proteins. They both required specific antibodies to interact with the target and
usually measured a single protein in each experiment. On the other hand, mass spectrometry can
identify and quantify thousands of proteins, as well as post-translational modifications, in a single
experiment. Note that because different peptides have different ionization efficiencies,
peptides/proteins frequently can’t be compared within the same experiment but can be compared
across different experiments. Thus, it is a relative quantification. The quantification can be done
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using observed signals or isotope labeling to combine different samples into one MS run. Currently,
available isotope labeling techniques include stable isotope labeling by amino acids in cell culture
(SILAC)68, dimethyl labeling69, isobaric tag for relative and absolute quantitation (iTRAQ)70, and
tandem mass tags (TMT)71, 72. At the moment, TMT allows up to 16 plex, which vastly increases
the capacity to study multiple disease conditions. The most significant advantage of using massspectrometry for quantification is being able to monitor thousands of proteins at the same time. As
a result, we can identify protein binding partners and monitor global population changes under
different conditions. Furthermore, with the sensitivity increased and the development of single cell
measurement, we also have the capability to discuss the localization of proteins73.

1.3.1.2 Turnover Rate
Protein concentration differences in fact reflect the change in synthesis and degradation
(Figure 3). The dynamic between synthesis and degradation is essential to understand where
changes occur with different biological events74. For example, once the development has been
completed, the protein concentration should maintain at a constant level for a healthy mature
organism. Thus the synthesis rate should be equal to the degradation rate75. On the other hand, it
has been observed that the protein synthesis rate decreased in old age76. The synthesis and
degradation can be derived from turnover, the half-life of protein

77

when combined with

concentration. Protein turnover studies were frequently done in the 1930s’ when the radioactive
isotopic tracer technique was applied for proteins

78, 79

. Nowadays, advanced mass spectrometry

and computational power make it possible to analyze the isotopic envelope of a given peptide. As
a result, stable isotope
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N, 13C, or 2H77, 80-82, are commonly used in the forms of an amino acid,

carbon source, or water78.
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1.3.2 Measurements of protein Quality
1.3.2.1 Structure and Functionality
Solving the 3D structure of proteins has been one of the top tasks for biochemists. While
gene engineering techniques provide information regarding a protein’s function in different
domains or at a specific site, a protein’s 3D structure is critical to understanding its nature and how
it performs its given tasks. Traditionally, a protein’s 3D structure is solved by x-ray crystallization,
Electron Microscopy (EM), or Nuclear Magnetic Resonance (NMR). These techniques give
accurate and high-resolution 3D structures but are also time-consuming. Another alternative is
using algorithms to predict protein structure. In 2021, the AlphaFold Protein Structure Database
was launched, and the predicted 100,000 3D structures of proteins from 21 species were released
to the public83, 84. As it is an exciting progression for the field, yet the predicted structure still only
represents a protein in isolation and cannot reflect changes in a protein’s conformation due to
native environmental factors like ligands or binding partners.
On the other hand, structural proteomics methods can report such native conformation
information. These include using crosslinking, photoaffinity labeling, limited proteolysis,
chemical protein modification, and hydrogen/deuterium exchange, typically coupled with mass
spectrometry, to learn how protein complexes are formed and how proteins interact structurally85.
The MS-based structural techniques allow us to monitor surface changes when proteins interact
with other ligands under physiological conditions. In addition to learning native structure, the MSbased studies also allow us to observe hundreds of different post-translational modifications (PTM)
in the proteome. This is important because PTMs can alter a protein’s native structure and function.
In many cases, PTMs play an essential role in biochemical signaling. For example, kinases transfer
a phosphate group to another protein to activate/deactivate the receptor protein’s binding to other
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proteins. Thus, phosphorylation and other PTMs can be like the on/off switch of protein signaling
pathway86, 87. The combination of high-resolution 3D structure and protein surface change in vivo
allows us to visualize how proteins work and piece out the mechanism of diseases.

1.3.2.2 Protein Stability
The studies of protein structure and function teach us the mechanisms behind biological
events (how proteins should work). As we investigate disease or mutation effects, we need a way
to quantify whether a protein is present and whether it is doing its job. As previously mentioned,
protein folding is an energy-driven process. The native functional proteins are stabilized when the
free energy (Gfolding) is at the minimum (Figure 4). Since Gfolding , which is also referred to as
protein folding stability (PFS), is directly related to proteins’ structure and functionality88-93, it can
be used as a quantifiable metric to evaluate whether the protein is folded correctly; in order words,
the protein’s quality. Traditionally, the protein folding stability is measured using Differential
scanning calorimetry (DSC), circular dichroism (CD) spectroscopy, or thermal shift assay
(ThermoFluor)94, 95. The central idea behind CD and ThermoFluor is to denature protein gradually
and find the denature midpoint (C1/2). The denature midpoint is where the native and unfolded
protein are in 1 to 1 ratio35. It represents the resistance of the protein to the denaturation caused by
chemical or heat, and is proportional to PFS (∆Gfolding= -m * C1/2)96. These techniques are well
defined and have good resolution, thus are often used in drug studies to understand protein-ligand
interaction and protein folding97. However, the most significant limitation of these techniques is
that they measure the average changes of the most abundant proteins in a mixture and, therefore,
are difficult to use in physiological conditions. For example, DSC can measure the stabilities
within a protein mixture and identify perturbations due to disease states
15

95, 98, 99

, but can’t

differentiate individual protein’s contribution to the stability sum from a single experiment.
On the other hand, MS-based techniques can measure PFS for individual proteins in a
complex protein mixture, allowing comparisons of PFS across the proteome under different
conditions. The MS-based techniques can be separated into two categories: thermal-denaturation
base and chemical denaturation-based. Thermal denaturation-based techniques (e.g., thermal
protein profiling (TPP)100,

101

, limited proteolysis-mass spectrometry (LiP-MS102)) denature

protein homogenate using a gradient of heat to aggregate proteins103. As the heat increases, more
protein aggregations form. Then, the soluble proteins in each temperature fraction are identified
and quantified by MS. The denaturation curve is plotted using the signal intensity of peptides from
soluble proteins. Thermal denaturation-based techniques are robust and widely used, but the PFS
measured is the average of the whole protein. In contrast, chemical denaturation-based techniques
(e.g., stability of proteins from rates of oxidation (SPROX96, 104, 105), Iodination Protein Stability
Assay (IPSA)) denature protein homogenate using a gradient of denaturant (GdmCl), and then
covalent modify surface amino acids. The denaturation curve is plotted using the signal intensity
of the peptide modified by the modifier. The efficiency and location of the modification reaction
are critical parameters for chemical denaturation-based techniques, because they provide localized
(modification site-specific) PFS information. These MS-based techniques not only provide the
protein folding stability information (Table 2), which quantifies a given protein’s quality, but also
make it possible to have a holistic view of quality changes of the proteome.
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Table 2 Comparison of Protein Quality Evaluation Techniques
X-ray
crystallization
Structure/Function
ality

Circular
dichroism

Ms-thermal
denaturation

Ms-chemical
denaturation

Stability

Stability

Stability

Single protein

Single protein

Proteome (1000+)

Proteome (1000+)

No

No
Thermal or
Chemical

Yes

Yes

Thermal

Chemical

---

1000+ points

~10 points

~10 points

Signal

---

Wavelength (nm)

Mass to charge
ratio (m/z)

Reporter

---

---

Soluble peptide

Other limitation

Low throughput

Low throughput

Not applicable to
serum

Mass to charge
ratio (m/z)
Covalent
Modified peptide
(e.g., oxidized
methionine)
Chemical
efficiency and
peptide sequencedependent.

Type of quality
Protein
population
Cellular context
Denature
approach
Denaturation
curve resolution

---

1.3.3 The Achievement and the Gap
It is encouraging that MS-based techniques are available for studying each protein
homeostasis controlling step in the proteome and have accelerated our understanding of disease
mechanisms. We had progressed from studying a single protein or proteins in one single pathway
to studying the networking effect of the entire proteome under different conditions. Yet, a systemic
view of protein homeostasis is still lacking, and the exact mechanisms of protein homeostasis are
still unsolved. To close this gap, we need a model combining synthesis, folding, and degradation
measurements altogether.
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1.4 The Kinetic Model of Protein Homeostasis
Due to technical limitations, scientists often need to minimize the number of variables and
simplify analytical models so the connections between the cause and the effect can be tested. Such
simplified approaches only reveal a portion of the disease mechanisms. Thus, a holistic evaluation
is needed. That is why there has been increased attention to protein homeostasis, the state when
protein synthesis, degradation, folding, localization, and modification are in functional balance106.
Incredibly, our understanding of the protein homeostasis controlling steps has significantly
advanced in the last decade. However, it is time for us to take a systems biology view, which seeks
to integrate information from many individual factors in the system and then form a holistic
understanding of the mechanism as a whole12. The holistic view will allow us to describe protein
homeostasis control and to help us battle diseases, particularly age-related diseases, and have better
life quality.
The strength of the kinetic model to quantify the protein homeostasis control is that it
provides a basis for experimental design and interpretation of results (Figure 2). According to the
model, protein homeostasis is highly related to the ratio of the concentration of correctly folded
protein [Pcorrect] versus the concentration of misfolded/aggregated protein [Paberrent]. Higher
concentrations of the correct folded protein indicate better cellular control of in vivo protein
homeostasis. Thus, our model is built to compare the [Pcorrect] and [Paberrant] in the proteome, by
linking the concentration of protein ([Ptotal]), mRNA ([mRNA]), and tRNA ([tRNA]), as well as
the rates of each step: tRNA charging (kCharge), synthesis (ksyn), folding (kfold), unfolding (kunfold),
misfolding(kmisfold), refolding (krefold), degradation of correct folded protein(kdeg1), and degradation
of protein aggregation (kdeg2). Based on the literature observations in neurodegeneration 107, 108 and
aging

109-111

, we expect that there are individual proteins will lose protein homeostasis first, but
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systems-level connections are unknown. By monitoring the ratio [Pcorrect] and [Paberrant], we can
identify individual proteins that perturb protein homeostasis and understand how the entire
proteome responsds to those perturbations. We can further understand the regulatory actions which
maintain the equilibrium between [Pcorrect] and [Paberrant]. For example, if the equilibrium of
[Paberrant]/[Pcorrect] increases, is it to an increase in kmisfold, or a decrease in krefold or kDegradation2?
The mathematic derivation of rate constants in this kinetic model (Figure 2) is based on
three assumptions:
1) The total protein concentration is constant for the adult organism in vivo 10, 112, thus:

𝒅[𝑷𝑻𝒐𝒕𝒂𝒍 ]
𝒅𝒕

=

𝒅[𝑷∗ ]
𝒅𝒕

+

𝒅[𝑷𝑪𝒐𝒓𝒓𝒆𝒄𝒕 ]
𝒅𝒕

+

𝒅[𝑷𝑨𝒈𝒈𝒓𝒆𝒈𝒂𝒕𝒆 ]
𝒅𝒕

=𝟎

Equation 1

2) Folding and unfolding (kfold, kunfold, kmisfold, krefold) are much faster than synthesis (ksyn)
and degradation (kdeg1, kdeg2)113, 114. Therefore, the concentration of unfolded protein
[P*] from nascent peptide is effectively zero; and the ratio of correctly folded to
misfolded protein, [Pcorrect]/[Paberrant], is constant during the measurement. Thus:

𝒅[𝑷𝑻𝒐𝒕𝒂𝒍 ]
𝒅𝒕

=

𝒅[𝑷𝑪𝒐𝒓𝒓𝒆𝒄𝒕 ]
𝒅𝒕

+

𝒅[𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ]
𝒅𝒕

=𝟎

, and [𝑷𝒕𝒐𝒕𝒂𝒍 ] = [𝑷𝒄𝒐𝒓𝒓𝒆𝒄𝒕 ] + [𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ]

Equation 2

Equation 3

3) The concentration of global variables like charged tRNA and free amino acid is
controlled by diet and metabolic sources115, is constant under the same experimental
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condition and within the same tissue for all proteins and therefor will be a constant
value that can be ignored in the protein-specific equations.
Putting all concentration and variables together, the change of [Pcorrect] and [Paberrant] can be found
using the following two equations:

𝒅[𝑷𝒄𝒐𝒓𝒓𝒆𝒄𝒕 ]

= 𝒌𝒔𝒚𝒏𝒕𝒉 [𝒎𝑹𝑵𝑨] − 𝒌𝒎𝒊𝒔𝒇𝒐𝒍𝒅 [𝑷𝒄𝒐𝒓𝒓𝒆𝒄𝒕 ] + 𝒌𝒓𝒆𝒇𝒐𝒍𝒅 [𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ] − 𝒌𝒅𝒆𝒈𝟏 [𝑷𝒄𝒐𝒓𝒓𝒆𝒄𝒕 ]

𝒅𝒕

Equation 4, and

𝒅[𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ]
𝒅𝒕

= 𝒌𝒎𝒊𝒔𝒇𝒐𝒍𝒅 [𝑷𝒄𝒐𝒓𝒓𝒆𝒄𝒕 ] − 𝒌𝒓𝒆𝒇𝒐𝒍𝒅 [𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ] − 𝒌𝒅𝒆𝒈𝟐 [𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ]

Equation 5.

Given that folded protein population [Paberrant]/[Pcorrect] is in equilibrium, total protein concentration
is constant. It is because kmisfold and krefold are stable, and the number of aggregation sites doesn’t
change during the timescale of the experiment. Therefore, we can describe [Paberrant]/[Pcorrect] using
the synthesis and degradation rate by substituting Equation 4 and Equation 5 into Equation 2
and like terms cancel. It gives us:

𝒅[𝑷𝒕𝒐𝒕𝒂𝒍 ]
𝒅𝒕

= 𝒌𝒔𝒚𝒏𝒕𝒉 [𝒎𝑹𝑵𝑨] − 𝒌𝒅𝒆𝒈𝟏 [𝑷𝒄𝒐𝒓𝒓𝒆𝒄𝒕 ] − 𝒌𝒅𝒆𝒈𝟐 [𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ] = 𝟎

, and 𝒌𝒔𝒚𝒏𝒕𝒉 [𝒎𝑹𝑵𝑨] = 𝒌𝒅𝒆𝒈𝟏 [𝑷𝒄𝒐𝒓𝒓𝒆𝒄𝒕 ] + 𝒌𝒅𝒆𝒈𝟐 [𝑷𝒂𝒈𝒈𝒓 ]

Equation 6

Equation7.

On the other hand, the turnover of Ptotal is defined as the average of the synthesis and degradation
rates:
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𝑇𝑢𝑟𝑛𝑜𝑣𝑒𝑟 =

(𝑘𝑠𝑦𝑛𝑡ℎ [𝑚𝑅𝑁𝐴]+𝑘𝑑𝑒𝑔𝑇𝑜𝑡𝑎𝑙 [𝑃𝑡𝑜𝑡𝑎𝑙 ])
2

Equation 8

Based on assumption(1), we further infer that the synthesis and degradation rate is the same.
Thus, we can substitute the degradation terms with synthesis terms in equation 8, which gives:
𝑇𝑢𝑟𝑛𝑜𝑣𝑒𝑟 =

2∗𝑘𝑠𝑦𝑛𝑡ℎ [𝑚𝑅𝑁𝐴]
2

Equation 9

We can do the same substitute to the synthesis therm. So, suppose we measure the protein
turnover, [mRNA], and [Ptotal]. In that case, we can calculate the synthesis (Equation 10) and
the total degradation (Equation 11) rate constants for any protein in any biological system:
𝒌𝒔𝒚𝒏𝒕𝒉 =

𝑻𝒖𝒓𝒏𝒐𝒗𝒆𝒓
[𝒎𝑹𝑵𝑨]

𝒌𝒅𝒆𝒈𝑻𝒐𝒕𝒂𝒍 =

Equation 10

𝑻𝒖𝒓𝒏𝒐𝒗𝒆𝒓
[𝑷𝒕𝒐𝒕𝒂𝒍 ]

Equation 11

We can further break the degradation constant kdegtotal into the respective rates kdeg1 and kdeg2,

𝑘𝑑𝑒𝑔𝑇𝑜𝑡𝑎𝑙 = 𝑘𝑑𝑒𝑔1 + 𝑘𝑑𝑒𝑔2

Equation 12

If we know the concentrations of the different protein populations [Pcorrect] and [Paggregate]. By
substituting equation 10 to the 𝑘𝑠𝑦𝑛𝑡ℎ [𝑚𝑅𝑁𝐴] in equation 7, we get:

𝑻𝒖𝒓𝒏𝒐𝒗𝒆𝒓 = 𝒌𝒅𝒆𝒈𝟏 [𝑷𝒄𝒐𝒓𝒓𝒆𝒄𝒕 ] + 𝒌𝒅𝒆𝒈𝟐 [𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ]
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Equation 13

Rearrange equation 13, we get:

𝑘𝑑𝑒𝑔1 [𝑃𝑐𝑜𝑟𝑟𝑒𝑐𝑡 ] = 𝑇𝑢𝑟𝑛𝑜𝑣𝑒𝑟 − 𝑘𝑑𝑒𝑔2 [𝑃𝑎𝑏𝑒𝑟𝑟𝑎𝑛𝑡 ]

Dividing by [𝑃𝑐𝑜𝑟𝑟𝑒𝑐𝑡 ] and simplify, we get:

𝑘𝑑𝑒𝑔1 =

𝑇𝑢𝑟𝑛𝑜𝑣𝑒𝑟
[𝑃𝑐𝑜𝑟𝑟𝑒𝑐𝑡 ]

[𝑃𝑎𝑔𝑔𝑟 ]

Equation 14

− 𝑘𝑑𝑒𝑔2 [𝑃

𝑐𝑜𝑟𝑟𝑒𝑐𝑡 ]

To find [Pcorrect] and [Paggregate], we need to know the equilibrium (K) between the two folded
states. It can be quantified by measuring the Gfolding 116, 117. Classically this would be described
as:

∆𝑮𝒇𝒐𝒍𝒅𝒊𝒏𝒈 = −𝑹𝑻 𝐥𝐧

[𝑷𝐚𝐛𝐞𝐫𝐫𝐚𝐧𝐭 ]
[𝑷𝒄𝒐𝒓𝒓𝒆𝒄𝒕 ]

Equation 15,

By substituting [𝑃aberrant ] with equation 5, and [𝑃𝑐𝑜𝑟𝑟𝑒𝑐𝑡 ] with equation 4 to equation 15, we
get:

∆𝑮𝒇𝒐𝒍𝒅𝒊𝒏𝒈 = −𝑹𝑻𝒍𝒏

𝒌𝒎𝒊𝒔𝒇𝒐𝒍𝒅 [𝑷𝑪𝒐𝒓𝒓𝒆𝒄𝒕 ]−𝒌𝒓𝒆𝒇𝒐𝒍𝒅 [𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ]−𝒌𝑫𝒆𝒈𝟐 [𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ]
𝒌𝒔𝒚𝒏𝒕𝒉 [𝒎𝑹𝑵𝑨]− 𝒌𝒎𝒊𝒔𝒇𝒐𝒍𝒅 [𝑷𝑪𝒐𝒓𝒓𝒆𝒄𝒕 ]+𝒌𝒓𝒆𝒇𝒐𝒍𝒅 [𝑷𝑪𝒐𝒓𝒓𝒆𝒄𝒕 ]−𝒌𝑫𝒆𝒈𝟏 [[𝑷𝑪𝒐𝒓𝒓𝒆𝒄𝒕 ]]

Equation 16

Based on assumptions (2), the krefold and kmisfold are zero relative to the ksyn and kdeg, thus:

∆𝑮𝒇𝒐𝒍𝒅𝒊𝒏𝒈 = −𝑹𝑻 𝒍𝒏 𝒌

−𝒌𝑫𝒆𝒈𝟐 [𝑷𝒂𝒃𝒆𝒓𝒓𝒂𝒏𝒕 ]

𝒔𝒚𝒏𝒕𝒉 [𝒎𝑹𝑵𝑨]−𝒌𝑫𝒆𝒈𝟏 [[𝑷𝑪𝒐𝒓𝒓𝒆𝒄𝒕 ]]
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Equation 17

Solving equation 15 for [Paberrant], we get:

∆𝑮

Equation 18

[𝑷𝐚𝐛𝐞𝐫𝐫𝐚𝐧𝐭 ] = [𝑷𝑪𝒐𝒓𝒓𝒆𝒄𝒕 ] 𝒆−𝑹𝑻

By substituting equation 18 into equation 3, we get:

∆𝐺

[𝑃𝑡𝑜𝑡𝑎𝑙 ] = [𝑃𝑐𝑜𝑟𝑟𝑒𝑐𝑡 ] + [𝑃𝑐𝑜𝑟𝑟𝑒𝑐𝑡 ] 𝑒 −𝑅𝑇

Equation 19,

Solving equation 19 for [𝑃𝑐𝑜𝑟𝑟𝑒𝑐𝑡 ], we get:

[𝑃𝐶𝑜𝑟𝑟𝑒𝑐𝑡 ] =

[𝑃total ]
∆𝐺

−
1+𝑒 𝑅𝑇

Equation 20

From equation 20, we can find [Pcorrect] using protein concentration and protein folding
stability. Knowing [Pcorrect], we can then calculate the [Paberrant] using equation 16 with the protein
folding stability value. Then, we will be able to monitor the ratio of [Paberrant]/ [Pcorrect] in cellular.
As mentioned before, the concentration change reflects the bias in the rate of synthesis and
degradation. Thus, it is important to examine the rate associated with [Paberrant]/ [Pcorrect] to
truly understand the mechanism using equations 13 and 17.
Using this kinetic protein homeostasis model, we can 1) compare how the ratio of [Pcorrect]
and [Paberrant] changes when synthesis and degradation rates change for individual protein/gene and
2) find the proteins which are more sensitive or affected earliest due to the loss of protein
homeostasis. From a problem-solving perspective, this model not only allows us to spot when the
protein homeostasis is declined and make diagnoses but also provides insight into how the protein
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homeostasis is lost and helps develop treatments. We live in an era when age-related diseases and
the negative effect on the stability of human society become more profound. It has become even
more critical to have a holistic view of the loss of protein homeostasis so we can develop
comprehensive treatment. We believe that the kinetic protein homeostasis model proposed here is
the first step we should take in resolving these life-threatening and heart-breaking diseases.

1.5 Protein Stability of Human Serum Proteins
This chapter has summarized the irregular protein function from both quantity and quality
aspects, reinforced the importance of protein homeostasis control, and introduced a kinetic model
of protein homeostasis that can provide us with a holistic view of the disease mechanism. Next,
we will focus on studying protein homeostasis in human subjects in the following chapters.
Participating in human studies is probably one of the biggest goals for any biochemist
because it is the only model that can truly reflect the mechanism behind human diseases. However,
we are limited in what samples are available. The most accessible sample type is human blood
serum. Blood circulates our bodies, traveling between systems and organs, not only to deliver
metabolites, but also passage signaling molecules. Blood serum carries abundant biological
information regarding our health status, and the harm to human subjects is minimal. Thus, it is the
most used biopsy for diagnosis. The blood test is the initial screening for any suspicious diseases:
pregnancy, infection, anemia, diabetes, heart diseases, Alzheimer’s disease118, cancer, and the list
continues.
There has been a tremendous amount of work put into serum biomarker discovery.
However, as discussed earlier, current biomarker discovery is heavily focused on protein
concentration. Often, by the time the irregular concentration of a protein is detectable, the disease
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is already fairly advanced and hard to stall or reverse. As previously mentioned, proteins’ proper
function is determined by their native structure and protein folding stability. Thus, it is critical to
investigate protein quantity and quality to understand a disease. Since there are already many
concentration studies done on human serum, here we will focus on protein quality metrics.
Chapter 2 proposes a kinetic protein homeostasis model tailored to human transthyretin
(TTHY), the protein responsible for several diseases, including cardiac amyloidosis. TTHY is one
of the top 50 abundant serum proteins. Functional TTHY is a tetramer. When the tetramer is
unstable, the monomers disassociate from each other and form aggregation. Because it is a protein
misfolding/aggregation disease, TTHY is an excellent application of the kinetic protein
homeostasis model discussed in section 1.4.
Chapter 3 examinates the serum proteins’ thermal stability difference between
rheumatoid arthritis and

non- rheumatoid arthritis

patients

using Differential

Scanning

Calorimetry (DSC). It also discussed the structural change of human serum albumin observed
between the two groups using the MS-based protein footprinting approach.
Chapter 4 introduces the Iodination Protein Stability Assay (IPSA), a novel MS-based
assay used to measure the protein folding stability, and its application to healthy human serum.
IPSA was built on the ideas of chemical denaturation and protein footprinting. In comparison to
other similar assays, IPSA has higher protein coverage and can track the protein folding stability
change within an individual protein’s sequence. To our best knowledge, this study is the first to
measure the protein folding stability of proteins in the human serum proteome.
I sincerely hope that as readers read through this dissertation, they will have an increased
understanding of the importance of the quality aspect of protein homeostasis, as well as an
increased desire to include such an aspect in their studies.
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CHAPTER 2: PROPOSING A MINIMAL SET OF METRICS AND METHODS TO
PREDICT PROBABILITIES OF AMYLOIDOSIS DISEASE AND ONSET AGE IN
INDIVIDUALS

2.1 Chapter Summary
This chapter proposes a model tailored from the kinetic model of protein homeostasis
introduced in chapter 1 to study transthyretin-mediated amyloidosis. We reviewed the current
known mechanism of transthyretin-mediated amyloidosis and proposed a study approach that
can measure the quality difference between different transthyretin’s mutation stages, as well as
monitor if the transthyretin amyloidosis has been developed at the early stage. Besides some
grammar corrections, the content is identical to the manuscript that was published in Aging
(Volume 12, Issue 22) in November 2020 ( https://doi.org/10.18632/aging.202208).

2.1.1 Authors in Order of Contribution
Richard S. Criddle, Hsien-Jung L. Lin, Isabella James, Ji Sun Park, Lee D. Hansen, John
C. Price1

2.1.2 Contributions of Major Authors
Drs. Criddle and Lee approached us and expressed their interest in using our kinetic protein
homeostasis methods to study transthyretin-mediated amyloidosis. Since then, we have used
human serum as the model for developing protein quality assay. I was involved in the discussion
of this transthyretin-specific model. I collected and analyzed preliminary data used to build the
TTR protein homeostasis model, which was presented in this paper. I also reviewed different
approaches used to measure protein folding stability.
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2.2 Abstract
Many amyloid-driven pathologies have both genetic and stochastic components where
assessing the risk of disease development requires a multifactorial assessment where many of the
variables are poorly understood. The risk of transthyretin-mediated amyloidosis is enhanced by
age and mutation of the transthyretin (TTR) gene, but amyloidosis is not directly initiated by
mutated TTR proteins. Nearly all of the 150+ known mutations increase dissociation of the
homotetrameric protein structure and increase the probability of an individual developing a TTR
amyloid disease late in life. TTR amyloidosis is caused by dissociated monomers that are
destabilized and refold into an amyloidogenic form. Therefore, monomer concentration, monomer
proteolysis rate, and structural stability are key variables that may determine the rate of
development of amyloidosis. Here we develop a unifying biophysical model that quantifies the
relationships among these variables in plasma and suggest the probability of an individual
developing a TTR amyloid disease can be estimated. This may allow quantification of risk for
amyloidosis and provide the information necessary for the development of methods for early
diagnosis and prevention. Given the similar observation of genetic and sporadic amyloidoses for
other diseases, this model and the measurements to assess risk may be applicable to more proteins
than just TTR.

Key words: Amyloidosis, Protein folding, Transthyretin, Proteostasis
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2.3 Introduction
The goal of this article is to describe how a minimal biophysical model of amyloidosis can
guide the diagnosis and treatment of relevant diseases. Towards that end, we first go over the
literature support for the model. We then describe current experimental methods to make the
necessary measurements. Finally, we discuss the way the application of this model could change
our understanding of the etiology and treatment of TTR amyloidosis specifically. Earlier reviews
1-5

provide extensive coverage of the fundamental information available from laboratory and

clinical work on amyloidosis. Therefore, brief summaries of relevant information on the TTR
protein properties and TTR amyloid diseases are given here, with only limited further references.

2.3.1 Transthyretin (TTR) protein amyloid
Human transthyretin (TTR, Uniprot # P02766) is a tetrameric, beta-sheet-rich, blood
protein important in the transport of thyroxine and retinol. Blood-borne TTR is produced and
secreted from the liver predominantly, although the choride plexis of the brain does express high
amounts 6. In plasma, the TTR tetramer is in dynamic equilibrium with a monomeromeric form
(Figure 1), with the degree of dissociation dependent on individual genetics and exogenous factors
like the binding of small hormones. TTR is less stable in monomeric form. TTR monomers may
misfold and be incorporated into supramolecular arrangements of beta-sheets known as cross-beta
structures 7-10. These cross-β assemblies are stabilized by an extensive network of hydrogen bonds
that cause them to form insoluble amyloids and resist proteolysis. Initially, misfolding is a
spontaneous process 11, 12. Once present, TTR oligomers may act in a prion-like fashion 13, 14 to
catalyze further misfolding of TTR into cross- assemblies that accumulate into the fibrils and
larger TTR amyloids as observed with multiple other amyloidoses 7, 15.
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Figure 1- Minimal kinetic mechanism for TTR homeostasis
TTR unfolded* is a transient intermediate that may not accumulate to a measurable degree. It is
assumed that degradation of fibrils and aggregate is negligible compared to degradation of
monomer (kDeg2<<<kDeg1)

2.3.2 Biological factors promoting amyloidosis
Three general factors have been linked with certainty to the development of TTR
amyloidosis: age, gender, and stability of the TTR tetramer. Development of TTR amyloidosis
increases with age, occurs more frequently and earlier in men than women, and is enhanced by
mutations that decrease the structural stability of TTR tetramers 1-5. It is unknown how these factors
impact the half-life in plasma. The removal pathways have not been fully characterized, but in rats
occur predominantly in the liver

16

. TTR can be removed from the plasma by proteolysis of

dissociated monomers, and by aggregation into fibrils, −amyloids, and amyloid deposits in
tissues. The rates and mechanisms for the removal of fibrils and amyloid deposits are poorly
understood if, indeed, such pathways are significant. The relative amounts of TTR removed via
39

these pathways depend on the relative rates of two processes, proteolysis and amyloid formation.
Both are preceded by tetramer dissociation to monomers (Figure 1). If proteolysis is rapid enough
to maintain TTR monomer concentration sufficiently low, transformations leading to amyloid
deposits are not significant. With rapid protease activity, TTR monomer concentration in plasma
is determined by tetramer stability. But when protease activity decreases relative to synthesis,
monomer accumulates and can aggregate. The aggregation has an nth order dependence on
monomer concentration, and even a small increase in monomer concentration greatly increases the
probability of oligomer formation 14.
Amyloid accumulation can be slowed by small molecules which bind and stabilize the
tetramer (tafamidis, diflunisal, and AG10) and limit monomer formation 17, 18 and thus slow but
do not cure the disease. Another treatment approach arises from the observation that the TTR
plasma concentration in an individual is maintained at a nearly constant value both before and after
amyloidosis develops

19, 20

. The rate of removal due to protein degradation generally decreases

with age 21-23. It is expected that if proteolysis slows to where it cannot keep up with the rate of
formation of monomers, TTR is removed by the formation of fibrils and −amyloid deposits. We,
therefore, hypothesize that the age-related imbalance in proteolysis initiates TTR amyloid diseases.
Identifying the proteolysis pathways would provide the next step toward developing a preventive
cure for TTR amyloidosis.

2.3.3 Individual differences in the development of amyloidosis
Differences in lifestyle factors like diet, internal physiology, and mutant variants contribute
to individual differences in the timeline of amyloidosis development. All three factors
quantitatively affect the dissociation of the tetramer into monomer
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9, 24

, and because removal

presumably proceeds via monomer, the relative rates of proteolysis and aggregation differ among
individuals. Any TTR mutation, physiological condition, or exogenous factor that stabilizes the
TTR tetramer also decreases monomer concentration. This favors a smaller ratio of aggregation
rate to proteolysis rate, which delays or prevents amyloidosis. Based on clinical reports, we expect
physiological differences such as differences in plasma proteins and small binding molecules to
1, 3, 25-29

affect tetramer stability and thus development of amyloidosis

. These physiological

differences may explain differences in the age of onset in men and women, but the in vivo studies
required to quantitate these effects have not yet been done. Exogenous factors related to life-style
and diet which modify metabolites and hormone signaling may also be important modulators of
amyloidosis, but the significance of these factors is also unknown.
Mutations in the gene coding for TTR were evolutionarily selected to enhance its role as a
transporter of thyroxine and retinol but play an important role in amyloidosis. Since TTR mutations
affecting amyloidosis become evident after the age of reproduction, no selective Darwinian
pressure hindered the acceptance and propagation of mutations that affect amyloidosis as long as
the mutations had no substantial effect on transport functions. As a consequence, the TTR gene
exhibits a large number (150 and counting) of antagonistic variants and a few protagonistic
variants, such as T119M, V30M, and L55P.

30, 31

. The most common variant is designated as

‘wildtype.’
The many mutations of TTR proteins appear to have a minor effect on the ability of the
monomers to be incorporated into -fibrils and amyloids

9, 14

. All form remarkably similar

wrapped, lamellar cross -sheet structures 14, 31. Even though mutant changes in single amino acids
at the various locations on the TTR protein do not appreciably interfere with the formation of sheet aggregates, these same changes do cause different tissue tropisms and corresponding
41

differences in phenotypic expressions of the disease according to genotype

32

. For example, the

amyloids formed from wildtype TTR show a predominantly cardiac tissue tropism where the βamyloids accumulate in heart muscle. But, the symptoms often differ among individuals having
the same TTR mutation and may range from carpal tunnel syndrome to neuropathy, spinal stenosis,
gastrointestinal problems, Hashimoto’s disease, etc. and various combinations of these.
Some of the diversity in symptoms may arise because mutant subjects are frequently
heterozygous with wildtype and mutant TTR co‐expressed in equal amounts. Tetramer formation
from mutants produces mixed hetero/homo-tetramers (i.e. wt4; wt3mt1; wt2mt2; wt1mt3; mt4). When
the tetramers dissociate, and monomers aggregate into fibrils, both wildtype and mutant subunits
can be incorporated into the -sheet structured oligomers. The fibrils thus contain mutant-specific
variations in the protein structures at their surfaces that may create reactive surfaces which bind to
cellular membranes with complementary binding groups. Mutant-specific differences in
oligomer/fibril binding to cellular membranes could explain differing phenotypic patterns of TTR
amyloidosis.

2.4 An integrated model for transthyretin (TTR) amyloidosis.
Studies of dissociation of tetrameric TTR have implicated both kinetics and
thermodynamics in the amyloidogenic behavior of TTR. Two observations in the literature
suggest that focusing on kinetics may be important: 1) the concentration of monomer in
equilibrium with the tetramer is orders of magnitude lower than the concentration of tetramer 9, 26,
33-35

, and 2) the exchange rate of monomers between wild-type tetramers is much faster at 4°C than

at 25°C and even slower at 37°C 36. Taken together, these two observations indicate the tetramer
undergoes a fast dissociation followed by a temperature-dependent conformational change of the
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monomer. As a consequence of the conformation change in the monomer, at 4°C, the association
is much slower than the dissociation reaction and allows promiscuous mixing of monomers. This
model accounts for both the slow exchange rate and inverted temperature dependence.
Figure 1 graphically summarizes the relation of amyloidosis to TTR concentrations,
stabilities of TTR tetramers ((TTR)4), and fates of monomers (TTR). This graphic makes it clear
that quantifying the relative rates for monomer transformations is key to understanding the
development or lack of development of amyloidosis. The first step in the removal of TTR is the
dissociation of the tetramer to monomer. Monomers that are not removed by proteolysis
irreversibly aggregate into fibrils and −amyloid deposits. The path from monomer to −amyloid
deposits occurs extracellularly and may include misfolded monomers, protofilaments, filaments,
and fibrils, but it is generally agreed that monomers are folded into −structures before, or upon
their incorporation into, fibrils and maintain this structure in the fibrils and further into the
construction of amyloids 37.
Formalizing a minimal kinetic mechanism (Figure 1) allows us to build a quantifiable
model. Assuming the rate of dissociation and association between monomer and tetramer is fast
relative to the rates of proteolysis and aggregation, the rates of formation and removal of TTR
from plasma are described by the following equations.
Amino acids → (TTR)4

d[(TTR)4]/dt = +ksynthesis

(Equation 1)

TTR → amino acids

d[TTR]/dt = -kDeg1[TTR]

(Equation 2)

TTR → growth of TTR aggregates

d[TTR]/dt = -kaggregate[TTR]

(Equation 3)
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Assuming the rate of production of TTR tetramer (equation 1) is constant, proteostasis is
maintained by balancing the rates of removal (equations 2 and 3) with the rate of production, and
therefore the sum of the rates of reactions 2 and 3 must equal 4*ksynthesis (equation 4).

kDeg1[TTR] + kaggregate[TTR] = 4(ksynthesis)

(Equation 4)

Solving for the concentration of monomer, [TTR] gives

(Equation 5)

[TTR] = 4(ksynthesis)/(kDeg1 + kaggregate)

Equation 5 suggests the concentration of TTR monomer depends on the relative values of
the rate constants for the production and removal processes. The removal rate constants change
with conditions that affect the rates of removal of the monomer. In the absence of aggregate
formation, equation 5 predicts that the plasma monomer concentration is a constant that depends
solely on the stability of the tetramer. Also, the ratio of ksynth to kDeg1 may differ between
individuals, so the concentration of monomer may differ as well. Therefore, an individual’s TTR
amyloidosis risk could be assessed by measuring the individual’s serum TTR concentration and
the stability of their TTR tetramer with respect to the monomer. The greater the concentration of
tetramer and the lower the stability, the greater the chance that amyloid deposits will cause disease
earlier in life. The ratio of a quantitative measure of tetramer stability to TTR serum concentration
over time in a single individual (longitudinal) or across populations (cross-sectionally) at specific
ages is thus predicted to be a useful index of the likelihood of an individual developing a TTR
amyloid disease later in life. Individuals with the most destabilizing mutations or cellular
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conditions in which amyloidosis is initiated at earlier ages would need to be compared as a unique
population cross-section or longitudinally.
These relative stabilities in combination with the frequently observed fact that the
unfolding of protein tertiary and secondary structures are endothermic 38-40 allow us to construct a
Gibbs energy diagram for amyloidosis (Figure 2).

Figure 2-Gibbs energy diagram for dissociation/association reactions of TTR

(TTR)4 ↔ 4TTR ↔ 4TTRmis

(Equation 6)

Here TTRmis is the misfolded monomer, either unfolded or a β-pleated sheet structure.
Figure 2 shows that any change that decreases the Gibbs energy of the tetramer increases the
activation energy for dissociation and decreases the concentration of the monomer, whether the
monomer concentration is determined by thermodynamics or by kinetics. Drugs that bind to and
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stabilize the tetramer, therefore, decrease the monomer concentration. The figure also illustrates
that misfolded monomers in vivo are tagged and hydrolyzed or aggregated because refolding and
reentering the tetramer structure has a very low probability, i.e., amyloids are very stable relative
to the unfolded intermediate. The likelihood of developing an amyloid disease is thus predictable
from the Gibbs energy for dissociation of the tetramer and the serum concentration of an
individual. Relative Gibbs energies of mutant variants and the effects of drug binding can be
measured in near in vivo conditions, as shown below.

2.5 Review of methods for determining TTR tetramer concentration and stability in serum
samples from individuals
Measuring an individual’s TTR concentration and stability within the context of their blood
serum is important clinically because it accounts for individual variations in environmental
variables like hormone concentration or TTR binding partners. Any variable which may change
TTR conformational distributions and stabilities would change the predicted risk of amyloidosis.
Although multiple methods exist to measure concentration and stability, we discuss
methods that seem to us most relevant and easiest to employ. Current mass spectrometry-based
methods represent a viable approach for monitoring both concentration and structural stability
within the complex mixture of blood. These methods are simple to multiplex and currently
employed for a wide variety of clinical diagnostics 41-43.

2.5.1 Concentration measurements:
Multiple high-quality reviews have been published on the topic of mass spectrometry for
measuring protein concentration 44-47. An optimized clinical assay for TTR might include a panel
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of internal standards composed of synthetic isotopically labeled peptides versions of natural TTR
peptides (Figure 3A). This type of test could allow for simultaneous measurement of TTR
concentration and test for known pathogenic mutations. Panels of internal standards for
concentration measurement are commonly used for small molecules like drugs of abuse as well as
protein-specific measurements

48

, and optimized assays are highly specific, require very little

sample, and can be run on thousands of samples around the clock. Little or no change beyond the
selection of the peptides to be measured is required to monitor TTR versus any other protein.

Figure 3-Structure of TTR (A)
Canonical WT TTR sequence, peptides frequently observed in mass spectrometry experiments
are shown in blue. Highlighted residues have published chemical modifications that could serve
as fold-stability markers. (B) The TTR monomer folds into two discrete beta sheets and a small
alpha helix (PDB structure 1BZE) (C) The consensus model of the tetramer has four monomers
(each in a different color) interacting along the edges of the beta sheets which would stabilize
the protein structure in these regions (Model incorporates PDB 1BZE and 1BZ8).
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2.5.2 Stability measurements.
Protein structural stability has historically been assessed as the resistance to denaturation 49, 50. As
shown in Figure 3, the monomer sequence Figure 3A folds into both beta-sheet and alpha-helical
secondary structures Figure 3B. The relative resistance to denaturation can be estimated based on
non-covalent bonding within the secondary structure, and would be different in an alpha helix
versus a beta sheet. If a reporter is located in a beta sheet rich region versus the alpha helical
region, different stabilities would be expected based on the location of the reporter and the folding
state (unfolded, monomeric, tetrameric, or amyloid) of the protein. For example, residues 95 to
101 are within the alpha helix and thought to be distant from any protein-protein interfaces in the
tetramer (Figure 3C based on reference

33

). Based on the structure in Fig 3, the alpha helical

section of the protein may have a similar structural stability regardless of protein oligomeric
structure (tetramer versus monomer). The edges of the beta sheets on the other hand gain new
binding interactions in the tetramer and would be significantly modified relative to the monomer.
In amyloid, there is an overall loss of alpha helical structure and increase in the beta sheet for each
monomer 5. Thus, measuring the fold stabilities along the entire sequence of the protein could be
valuable for differentiating between monomer, tetramer, and fibril/amyloid forms of TTR.
Further, measuring the TTR structural stability in the context of blood serum (in situ) is important
as ligands within the blood serum bind and stabilize the tetramer beta sandwich which could be
read out as a shift in the structural stability of these sections of the protein.
Several mass spectrometric techniques have been published recently which allow in situ
measurements of structural stability along the entire sequence of the protein 43, 51-53. These methods
can be generalized to chemical versus temperature denaturation of the protein (Figure 4). Both
methods can measure sequence specific stabilities across TTR within a complex mixture of
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proteins like blood serum. Both methods also measure individual unfolding curves within complex
mixtures by treating small aliquots to gradually increasing denaturation conditions. Each method
has individual advantages and disadvantages. Thermal is fast, requires minimal sample handling,
and uses the entire protein sequence as a reporter. However, the thermal mechanism functions
through a precipitation step that is not fully characterized and may change with unknown variables.
The chemical method uses covalent modification of specific amino acids to report unfolding. This
is an advantage in that all the protein stays in solution and both labeled and unlabeled forms of the
peptide can be measured and signal compared for substrate and product. The disadvantage of the
chemical method is that the distribution of modifiable amino acids is nonuniform across any
protein. For example, methionine labeling has been used to monitor chemical denaturation and
has the sensitivity to identify stability changes due to drug binding
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or secondary structure

differences 55. Unfortunately, only a single methionine is found in the N-terminal portion of the
TTR protein (Fig 3A). Fortunately, a variety of different labeling methods exist in the literature
that may be appropriate for monitoring protein structure 56.

Figure 4-Two methods to measure protein structure stability via mass spectrometry .
In A. concentration of the remaining soluble protein is measured, while in B. the relative amount
of modification for amino acid side chains is the reporter
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Most of the published studies using mass spectrometry unfolding assays have used yeast
or cell culture. To test whether these mass spectrometry methods might be appropriate for blood
serum we performed preliminary tests. We found the thermal denaturation technique was not
effective for blood serum. We tested temperatures up to 100 °C, but there was no evidence of
precipitation. This may be due to the extreme thermal stability of Albumin 57, stabilizing the rest
of the proteins in the serum. In comparison, proteins from tissue homogenate precipitated
efficiently beginning at 40C, and precipitation increased as predicted up to 70C, at which point
90% of the protein had precipitated from solution, as reported in the literature

52

. To test the

chemical denaturation method, we used guanidine denaturation and histidine modification by
iodine to assay blood serum. We observed differential behavior for several peptides and measured
significant differences in the denaturation midpoint of two different sections of TTR (Figure 5).
Although both of these sequences (A: 42-53, B:101-123) are expected to contain beta strands, the
peptide A has a lower overall stability (denatures at lower concentrations) in these conditions than
peptide B.

Figure 5-Denature Curve of TTR peptide
TTR structure causes modified susceptibility to denaturation for different parts of the sequence.
Individual measurements (triangles) were fit across the denaturant concentrations to calculate
the midpoint (vertical line) and confidence interval of the midpoint (shaded area)
50

After optimization of modification chemistry for residues in sections of interest, this type
of method has the potential to provide the stability measurements needed to assess risk of
amyloidosis. This will require significant effort to validate in a cross-sectional study, and we
expect that longitudinal measurements could be most fruitful if made throughout a subject’s
lifetime.

2.6 Discussion
There are more than 30 characterized amyloidosis diseases involving a variety of proteins.
While these diseases differ markedly in their physiological effects, there are common features in
their development. Multiple mutations within the various precursor proteins promote amyloidosis
(eg. TTR>150 known mutants, gelsolin>4, lysozyme>10, and fibrinogen>18)

58-61

. Most

amyloidogenic mutations change a single amino acid, yet these simple changes give rise to
multiple phenotypic disease symptoms that differ between different mutations of the same protein
and among individuals with the same mutation. The individual nature of the mutations in each of
these diseases presumably plays a direct role in determining differences in the oligomeric -sheet
structures of precursor protein and impacts the phenotypic expression of the diseases 62. All these
diseases have individual variability in age of onset, indicating that the mutation is not the triggering
factor for initiation of amyloidosis. The nature of factors initiating onset of amyloidosis is not
currently known for any of these diseases, However, the common features suggests that a model
developed for TTR amyloidosis may be applied in analysis of the other heritable amyloidosis
diseases.
The proposed model emphasizes that the relation between monomer concentration and
proteolysis is important to understanding development of amyloidosis. Spontaneous unfolding of

51

monomer is likely variant dependent or can be triggered by a change in the molecular environment
49

. The misfolding of monomer into -sheet and aggregation varies among individuals based on

genetics and lifestyle decisions which modify the concentration of endogenous small molecules
which stabilize the TTR tetramer. Therefore, our metrics of relative TTR tetramer stability in the
presence and absence of putative stabilizers should be measured in vivo or at conditions as close
to in vivo as possible.
Proteolysis is generally rapid enough to maintain the monomer at concentrations that
minimize aggregation. However, the age dependence for amyloidosis risk could be connected to
decreases in protease or chaperone activities that occur at older ages 21-23, 38. Decreases in protease
activity (kDeg1, Figure 6) and chaperone activity (kfolding and kdisaggradation) would increase monomer
concentration and increase the unfolding rate causing a greater fraction of monomer to aggregate.
This could explain why amyloidosis typically occurs later in life. The rate of proteolysis of TTR
has a linear dependence on the monomer concentration, but initiation of TTR aggregation has a
higher order dependence on monomer concentration, and growth of TTR aggregates likely causes
amyloid deposit growth rates to increase exponentially once deposition begins. An exponential
increase in rates of oligomer formation to maintain proteostasis in the face of the increase in
monomer concentration would explain the rapid progression of disease once symptoms are
apparent.
Accumulation of abnormal proteins is a common feature of senescent tissues

63, 64

. This

suggests that the decoupling of the synthesis, folding and proteolytic activities is general and
related to the protein quality control in cells

21-23

. But, decreased proteolysis and increased

misfolding may also be caused by modifications that make the altered proteins less susceptible to
proteolysis, e.g. amino acid side-chain modifications, chemical crosslinking and/or aggregation,
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may result in the altered proteins being poor substrates for the proteases. In cases where specific
proteins are chemically tagged for proteolytic turnover to maintain homeostasis, a decreased rate
of the tagging reactions could also cause a decreased turnover rate of specific proteins and an
increase in monomer concentration.

Figure 6-Age dependent changes leading to amyloidosis disease

Support for the contribution of cellular quality control as the initiating variable comes from
twin studies. Twins with the same mutation may express symptoms of amyloidosis at different
ages

28

. Relative rates of protein turnover vary among individuals, depending on gender, diet,

genetic background, etc. According to the model, individuals who maintain adequately high rates
of proteolysis of TTR do not get amyloidosis, but an “adequate” proteolysis rate is a function of
the stability of the tetramers of various mutants and individual physiology. An age-related decrease
in proteolysis rates of individuals with TTR destabilizing mutations increases monomer to the
threshold concentration for aggregate formation. This threshold is reached earlier and deposition
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of amyloids is maintained at higher rates with variants having less stable TTR tetramers in their
individual plasma background.

This could explain the findings that calorie restriction (which

reduces global protein synthesis 65-68) protects against amyloid deposition 69-71. Reducing synthesis
to match the diminished proteostasis capacity could result in many of the same benefits as
therapeutically increasing proteolysis and chaperone activity.
In current practice, TTR amyloidosis has been divided into two amyloid diseases referred
to as wild type and familial. Wild type is described as an “age-related, non-hereditary systemic
amyloidosis” that is induced by unknown factors to form amyloid deposits by wild type TTR
proteins. The familial disease is described as a separate disease that occurs as a consequence of
mutations of wild type TTR protein. We disagree with this separation because the wild type and
familial diseases share a common mechanism even though manifestations of the disease may
differ. The wild type TTR gene underwent Darwinian selection for transporting thyroxine and
retinol when reproductive age and life expectancy were much shorter than today and amyloidosis
had negligible effect. Any mutations in the TTR gene that did not have a significant adverse effect
on transport functions were accepted and propagated resulting in 150+ recognized mutant forms
of TTR that generally differ from wild type by a single amino acid. These mutant proteins may
enhance, decrease, or have no effect on TTR tetramer stability compared with wild type. All forms
of TTR, including wild type, can cause amyloidosis and the propensity for amyloidosis in people
with wild type TTR is just as heritable as it is for those with a mutant form. Thus, there is no reason
to consider wild type TTR amyloidosis and familial TTR amyloidosis as separate diseases.
Separate clinical trials of effectiveness of treatments for wild type TTR and familial TTR
amyloidosis are unnecessary and counterproductive. However, our model does not address why
various mutants often cause predominantly cardiac, or neurological, or other diseases and trials
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comparing treatments for differing diseases should be done. Individuals with the same mutant form
of TTR commonly exhibit different disease phenotypes because of differences in tissue tropisms.
Grouping TTR diseases by tropisoms running drug trials with (a) predominantly cardio, (b)
peripheral neuro, or (c) a combination of both reduces effort and increases efficiency. Our model
and experimental methods reported here offer a solution to this conundrum by rapidly
quantitatively examining properties of TTR variants in near in vivo conditions to evaluate drug
responses in individuals. The same general model and methods may also apply to other late-in-life
expressed amyloid diseases. Thus, we propose individual testing for predicting response to
treatment instead of clinical trials.
Current treatments for amyloidosis based on altering structural stability will not lead to a
cure. A cure requires identifying and correcting the factor(s) that are responsible for the changes
in relative rates of monomer removal and amyloid deposition. Our model does not identify these
factors but suggests metrics that that future research can use to interrogate the age-related changes
in protease activity, chaperones, post translational N-glycation, cellular energetics, oxidative
reactions, and glycosylation.
For example, glycosylation has been implicated in TTR amyloidosis 24, 72-74. Glycosylation
is a viable candidate to consider for an initiating event in TTR amyloidosis because (a) it is
commonly involved as a post translational signal in biochemical pathways to activate or moderate
metabolic pathways 75, (b) glycosylation activity in human plasma is heavily influenced by gender
73

, (c) there is a general decrease in glycosylation activity with age 76. TTR is generally synthesized

and secreted from the liver without added sugars, though it has a consensus sequon for
glycosylation at Asn 98. Crystallographic data suggest that the glycosylation site in the folded TTR
tetramer may not be accessible to glycosylating enzymes and/or their substrates. However, some
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variant TTR tetramers (e.g., L12P, and to a lesser extent V30M) have altered folded structures that
expose Asn 98 and do get glycosylated

75

. Dissociation of tetramer to monomer (or partially

unfolded, or unfolded monomer) also causes structural changes that can make the sequon
accessible for glycosylation. If glycosylation is a factor in tagging TTR monomers for rapid
proteolytic degradation, decreased glycosylation activity could result in a sufficient buildup of
monomer to cause development of amyloidosis. The current data are insufficient to propose
decreased rates of glycosylation or other posttranslational modification as the causative factor in
triggering amyloid formation, but this scenario does emphasize that many additional plausible
examples of types of reactions must be considered in seeking the causative factor initiating TTR
amyloidosis.

We hope that this model and the proposed quantitative metrics to identify

amyloidosis early, will enable investigation of modified metabolic activities like glycosylation, as
well as a method to quantify treatment efficacy which will enable development of a real cure for
these diseases.

2.7 Summary
1. This biophysical model and proposed the measurement methods can be used directly with
current human subjects or with banked blood samples. We propose that it will be of great
benefit in current clinical trials to understand treatment efficacy.
2. The rate of synthesis of TTR is constant. For proteostasis, the rate of removal of TTR
must equal the rate of synthesis. TTR in plasma is largely in the tetrameric form, (TTR)4,
but dissociates to give very low, but significant concentrations of dimers and monomers.
3. Removal of TTR from plasma proceeds via monomers.
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4. Monomers undergo two processes that remove them from solution, proteolysis or
aggregation. The combined rates of these two pathways equals the total rate of monomer
removal, which is also equal to the rate of production of monomer via dissociation of
tetramer. Depending on the relative rates, either of the two reaction pathways could
account for anywhere from 100% to 0% of the rate of monomer removal.
5. The critical monomer concentration for aggregation is unknown, however the cause of
aggregation develops slowly over time. Once amyloidosis begins, the rate of
development of amyloidosis is determined by the rate of monomer incorporation into
various aggregates that lead to fibrils and amyloids.
6. Destabilizing tetramer by pleiotropic mutations leads to greater dissociation of monomer
and a higher, variant-dependent concentration of TTR monomer in plasma. Mutations are
not required for TTR amyloidosis formation; point mutations only modify the
equilibrium concentrations in Figure 6. Amyloidosis caused by wild-type TTR follows
the same mechanism as amyloidosis caused by variants of TTR and thus should be
considered as variants of the same disease for purposes of clinical studies.
7. Amyloidosis begins when the rate of TTR proteolysis decreases relative to the rate of
amyloid formation and monomer concentration increases sufficiently to allow significant
oligomerization into fibrils and amyloids. The cause of a decrease in the rate of
proteolysis of TTR remains to be identified.
8. When the tetramer is stabilized by drugs or stabilizing mutations, the concentration of
tetramer will increase in plasma to a steady-state level determined by the rate of
proteolysis.
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2.8 Methods:
2.8.1 Chemical denaturation:
Blood serum from a healthy human control was diluted with PBS to 10 mg/ml and divided
into 9 fractions containing 0.02 milliliters. We added 0.027 milliliter guanidine of different stock
solutions to each fraction to bring final guanidine concentration to 0, 0.4, 0.9, 1.3, 1.7, 2.2, 2.6,
3.0, 3.5M and partially unfold the proteins in the individual fractions as shown in Figure 4. This
mixture was allowed to incubate at 37°C for 30 minutes at which point iodine/KI solution (0.3
molar) was added to achieve final concentration of 2.9 nmole in 0.05 milliliter. The iodine-labeling
reaction proceeded for 10 minutes until 100mM imidazole was added to quench the reaction. At
this point high concentration guanidine (6M) was added to fully denature all protein. Tris(2carboxyethyl)phosphine (TCEP, final conc 10mM) was added to reduce disulfide linkages and
chloroacetamide (40mM final concentration) was added to cap the reduced cysteines. The mixture
was placed on top of a 30kD spin concentrator (VWR) and washed 2 times with ammonium
bicarbonate (25 mM, ph=8.5). Trypsin (mass spectrometry grade) was added to the mixture on
top of the filter and allowed to digest the protein overnight at 37°C. After digestion peptides were
spun through the filter and concentrated under vacuum for analysis by mass spectrometry.

2.8.2 Thermal Denature:
Blood serum was diluted with PBS to 2 mg/ml and 30uL volume was added to 10 PCR tubes.
A PCR thermocycler (Biorad T100) was used to create an equally spaced gradient of temperature
with 10 steps from 37 to 63 or 37 to 100 Celsius. Samples were incubated at these temperatures
for 3 minutes to partially unfold the proteins in the individual fractions, then cool down to 4°C for
3min to quench the reaction as shown in Figure 4. The samples were then removed from the
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thermocycler and spin at 14000xG at 4°C for 20mins to precipitate the aggregated protein. The
soluble fraction was collected for protein digestion. At this point high concentration guanidine
(6M) was added to fully denature protein. Tris(2-carboxyethyl)phosphine (TCEP, final conc
10mM) was added to reduce disulfide linkages and chloroacetamide (40mM final concentration)
was added to cap the reduced cysteines. The mixture was placed on top of a 30kD spin
concentrator (VWR) and washed 2 times with ammonium bicarbonate (25 mM, ph=8.5). Trypsin
(mass spectrometry grade) was added to the mixture on top of the filter and allowed to digest the
protein overnight at 37°C. After digestion peptides were spun through the filter and concentrated
under vacuum for analysis by mass spectrometry.
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CHAPTER 3: STRUCTURAL STABILITY OF HUMAN SERUM ALBUMIN IS
MODIFIED IN RHEUMATOID ARTHRITIS

3.1 Chapter Summary
This chapter continues exploring the quality aspect of protein. This study used mass
spectrometry to quantify the surface accessibility differences in human serum albumin (HSA)
between patients with and without rheumatoid arthritis (RA). We found certain residues are less
reactive in the RA group, indicating a structural change in HSA. Such structural changes, possibly
caused by ligand binding, stabilized HSA and explained the heat denature curve shift we observed.
Besides some grammar corrections and the difference in the numbering of figures and
supplemental data, the content is identical to the primary research manuscript that was resubmitted to PLOS ONE in June 2022.

3.1.1 Authors in Order of Contribution
Hsien-Jung L. Lin1*, David H. Parkinson1*, J. Connor Holman1, W. Chad Thompson1,
Christian N. K. Anderson1, Marcus Hadfield1, Stephen Ames1, Nathan R. Zuniga Pina 1, Jared N.
Bowden1, Colette Quinn2, Lee D. Hansen1, John C. Price1
* Authors contributed equally

3.1.2 Contributions of Major Authors
I was the project leader who coordinated and supervised all aspects of this study. This study
started before I joined the lab. The goal was to understand why the heat denature curves shift
between RA and non-RA subjects. Many previous undergraduate students had worked on this
project and had previously observed the PTM bias between groups. Most of the MS and HDC data
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had been collected, but the data analysis wasn’t comprehensive. With the belief that all
experiments done are worth being published, I took on the project intending to learn something
meaningful and publish. I started the analysis again from the beginning. In 2018, visiting professor
Dr. Jared Bowden suggested we look into the concentration bias of HSA's ligands. From there, we
came up with the hypothesis that HSA's ligand-binding difference changes its structure, thus
affecting melting temperature. I started a series of lipidomic experiments to learn if HSA carried
different lipid or same lipid but at different concentrations. Later, the wet lab responsibility was
transferred to my students, as I was primarily responsible for MS data collection and data
analysis/visualization. I wrote the initial submission manuscript, which integrates data from three
different fields: differential scanning calorimetry, proteomic, and lipidomic, to show the structural
and binding partners' change in RA. (The lipidomic data was removed in this version). The Cofirst author, David H. Parkinson, is responsible for most of the revisions and additional data
analysis in response to reviewers’ comments.
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3.2 Abstract
Differential scanning calorimetry (DSC) can interrogate changes in structure and/or
concentration of the most abundant proteins in a biological sample via heat denaturation curves
(HDCs). In blood serum, for example, HDC changes are a result of either concentration or altered
thermal stabilities for 7-10 proteins and has previously been shown capable of differentiating
between sick and healthy human subjects. Here, we compare HDCs and proteomic profiles of 50
patients experiencing joint-inflammatory symptoms, 27 of which were clinically diagnosed with
rheumatoid arthritis (RA). The HDC of all 50 subjects appeared significantly different from
expected healthy curves, but comparison of additional differences between the RA the non-RA
subjects allowed more specific understanding of RA samples. We used mass spectrometry (MS)
to investigate the reasons behind the additional HDC changes in RA patients. The HDC differences
do not appear to be directly related to differences in the concentrations of abundant serum proteins.
Rather, the differences can be attributed to modified thermal stability of the most abundant protein,
human serum albumin (HSA). By quantifying differences in the frequency of artificially induced
post translational modifications (PTMs), we found that HSA in RA subjects had a much lower
surface accessibility, indicating potential ligand or protein binding partners in certain regions that
could explain the shift in HSA melting temperature in the RA HDCs. Several low abundance
proteins were found to have significant changes in concentration in RA subjects and could be
involved in or related to binding of HSA. Certain amino acid sites clusters were found to be less
accessible in RA subjects, suggesting changes in HSA structure that may be related to changes in
protein-protein interactions. These results all support a change in behavior of HSA which may give
insight into mechanisms of RA pathology.
Key words: rheumatoid arthritis, serum albumin, differential scanning calorimetry, structure
stability, proteomic, post-translational modification, protein surface accessibility
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3.3 Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized
by non-articular changes, symmetrical polyarthritis, and congenital symptoms (1, 2). Despite the
prevalence of RA, the classification for the disease is considered definite only after the confirmed
presence of chronic inflammation of the connective tissue in one joint, no reasonable alternative
diagnosis, and scoring 6 or greater across the four different characterization domains (number of
joints involved, abnormal antibody count, elevated acute-phase response, and duration of
symptoms (3)). The late and tentative diagnosis of RA is mainly due to the elaborate, poorly
understood etiology of the disease and a complex interplay between genetic and environmental
factors. Effective RA management is correlated with early and aggressive treatment (2). Therefore,
it remains crucial to develop an accurate, quick, and inexpensive way to diagnose RA, preferably
without a tissue biopsy. The prognosis of RA patients depends heavily on early diagnosis since
current treatments only relieve symptoms and slow progress, but do not cure the disease. Thus, the
earlier the diagnosis, the better the prognosis for the patient.
Several low abundance proteins in human serum, such as C-reactive protein (4),
rheumatoid factor (RF) (5), anti-citrullinated peptide antibodies (ACPA) (6), and anti-keratin
antibody (AKA) (7) have been investigated for detection of pre-RA symptoms (5), but none have
been found to serve as a biomarker for RA initiation. These proteins correlate with autoimmunity,
but collectively make up an extremely minor percentage of human serum (<<1%), which often
results in low sensitivity (8). Other metabolites, such as glucose (9), high-density lipoprotein
(HDL) cholesterol (10) and vitamin D (11), have also been implicated in RA pathogenesis, but
have not been used for diagnosis.
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Current diagnostic tests for RA consist of measuring serum concentrations of rheumatoid
factor (RF) and cyclic citrullinated peptide (CCP). Although RF concentration is widely used and
the most accepted test for RA serologic diagnosis, it is not specific for RA (12). Elevated RF can
be found in many other diseases, including other autoimmune diseases (Sjogren’s syndrome,
systemic lupus erythematosus) (13, 14), chronic infections, cardiovascular disease, cancer, and
normal aging (15). The sensitivity and specificity of RF for RA diagnosis are 62% and 89%
respectively, and CCP’s sensitivity and specificity for RA diagnosis are 53-58% and 95-96%
respectively (8). The RF and CCP tests are useful, but diagnosis often cannot occur until the disease
has progressed significantly. Thus, more information about the causes of RA is needed to detect
and intervene in RA development earlier and more accurately.
In this study, we compare RA-positive (RA) patients to RA-negative (non-RA) patients,
all within a group of 50 who all came in for clinical testing because they were experiencing RAlike symptoms (Figure 1). Comparing RA and non-RA subjects within a closed symptomatic
group allows us to determine which proteomic changes come from RA-specific pathology, rather
than generic inflammatory factors. We hope to reduce the confounding effect of comorbidities so
that we can detect RA-specific differences. Here, we show our findings outlining RA-specific
serum proteome changes and we propose a model for an RA-induced increase in HSA stability
through potential binding partners, which we hope will offer valuable guidance in future research
looking for better RA treatments and diagnostic models.
Blood serum samples from subjects that had physician ordered RA panels were used
(n=50). Based on the clinical diagnosis, the samples are separated into an RA group (n=27) and a
non-RA group (n=23). DSC was used to obtain the HDC, and the curve shift was compared
between groups. LC/MS-MS experiments were performed to determine the mechanism behind the
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curve shift. Quantification and surface amino acid reactivity analyses were performed to determine
significant differences in serum proteins between RA and non-RA groups.

Figure 1-Experimental Flow

A potential method to understand disease-specific pathology is from calorimetric
thermograms (herein referred to as heat denaturation curves, HDCs) of patient serum obtained by
Differential Scanning Calorimetry (DSC) (16–21). HDCs of serum from patients with several
different diseases have been shown to exhibit reproducible shifts in the pattern of protein heat
denaturation that are unique for those diseases (22–31). Although no mechanistic information is
obtained, these differences must arise from changes in the concentrations and/or structures of the
most abundant proteins (~8 proteins) in the serum (32). In this study, HDCs were used to
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characterize the altered serum proteins in RA patients (clinically diagnosed according to symptoms
and various biomarker levels). A characteristic HDC shift was seen across samples, and there was
a significant relationship between RA diagnosis and HDC appearance. Mass spectrometry (MS)
was then used to identify proteomic differences in the RA vs. non-RA samples, and we also looked
for correlations between the proteome and HDC appearance (independent of RA diagnosis).
Together, these results allowed us to understand which changes in the RA proteome could be
attributed to the observed HDC differences.
We tested two possible mechanisms to explain this HDC shift (Figure 2). First, changes in
concentration of abundant proteins, such as human serum albumin (HSA), would alter the intensity
of high abundance protein peaks, changing overall HDC shape (22,33) (Figure 2A). In this study,
we focus primarily on HSA because it is the most abundant protein in plasma. Second, HDC shape
would be significantly altered by a change in thermal stability of abundant proteins, shifting their
melting temperatures. For example, loading HSA with a fatty acid (octanoic acid) increases the
melting temperature by 5 to 10 °C (34). Such changes in stability would most likely correlate with
a change in these proteins' tertiary structures and would be for a smaller portion of the total HSA
(35) (Figure 2B). We used MS to explore both concentration differences in HSA (and other
abundant proteins), as well as HSA tertiary structure changes (by looking at surface reactivity (36,
37)) as potential causes of the characteristic shift in the HDCs. As outlined below, our data support
a change in the HSA thermal stability (Figure 2B). The MS-detected differences provide
structural clues for HSA stability changes (38, 39).
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Figure 2-Two possible models explaining HDC shifts in RA subjects
The decreased peak ratio in RA samples could be explained by A) a relative HSA concentration
decrease, reducing HDC signal intensity, or B) a shift in HSA thermal stability, shifting the HSA
peak to the right, decreasing the first peak's intensity, and increasing that of the second peak. This
thermal stability could be the result of altered binding partners. The structural changes can be
seen through biased detection of surface modifications on HSA. When cargo is unbound (top right,
light green protein), binding sites are surface accessible for modification, when cargo is bound
(top right, dark green protein), these sites are occupied, reducing surface accessibility and ability
of these sites to be modified. These structural and functional differences at the molecular level
could be the explanation for the observed shift in HDCs.

3.4 Results and Discussion
We used a sample population of fifty anonymized serum samples from patients who
experienced joint inflammatory symptoms. Patients ranged from age 12 to 88, with a median age
of 50. Samples were not selected based on gender and the resulting sample set contained males
(n=13) and females (n=37), matching statistical prevalence of RA (40). The rheumatoid arthritis
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panel (41) was conducted for the serum samples by ARUP Laboratories, including a rheumatoid
factor (RF) and cyclic citrullinated peptide (CCP) test. Professional medical analysis of symptoms,
paired with the CCP and RF levels, classified the 50 samples as coming from RA (n = 27) and
non-RA (n = 23) subjects. (Table 1). Note that the serology results show only some of the factors
used for RA clinical diagnosis. Other factors (joint involvement, acute phase reactants, and
symptoms duration, etc. (42)) were used for diagnosis, but the supplementary diagnostic
information was not provided for this study.

3.4.1 Heat Denaturation Curves
Heat denaturation curves (HDC) were collected with a NanoDSC (TA Instruments, Lindon,
UT). Forty-seven HDCs were obtained (HDCs for three subjects were uninterpretable due to errors
during the sample injection). As seen in literature, HDCs for healthy subjects have two distinct
peaks around 63 degrees and 71 degrees, which correspond to the known melting points for HSA
and immunoglobulin proteins, respectively (30). The previous studies showed the low temperature
peak at 63°C is primarily a combination of HSA and haptoglobin (HAPT), in which HSA
dominates due to its much higher concentration (30). The high temperature peak at 71°C is
primarily a combination of Immunoglobulin G (IgG) and Immunoglobulin A (IgA) underlain by
the tail of the broad HSA peak (30). Healthy normal serum samples are reported in the literature
with a more intense HSA (low temp) peak at 63°C and a comparatively lower intensity Ig (high
temp) peak at 71°C (30). A separate study from Garbett et al. shows the 63 to 71 degree peak ratio
in a cohort of healthy samples to be 1.59 ± 0.04 (22).
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Table 1-Sample Information and Classification
Sample Information (Provided by ARUP laboratory)
Clinical
Sample
Age
Gender
CCP
value
RF
value
RA
name
diagnosis
B37
B38
B39
B41
B42
B43
B44
RF01
RF02
RF03
RF04
RF05
RF07
RF10
RF11
RF13
RF15
RF16
RF17
RF19
RF21
RF22
RF25
RF28
RF29
RF30
RF31
RF34
RF36
RF38
RF39
RF40
RF41
RF43
RF47
RF49
RF51
RF52
RF53
RF54
RF55
RF56
RF57
RF58
RF60
RF62
RF64
RF65
RF67
RF68

68
49
45
74
38
61
70
52
61
66
56
58
66
53
45
70
42
57
55
43
44
50
12
24
30
83
61
40
71
48
43
24
59
24
24
56
17
35
47
50
35
55
51
30
37
74
44
34
88
69

M
M
M
M
M
F
F
F
M
M
F
F
F
F
M
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
M
F
M
F
F
F
F
F
F
F
M
F
M
F
F
F
M
F
F
F

3
209
3
1
1
3
16
6
12
5
5
3
4
3
4
8
186
202
199
4
192
194
5
46
170
193
4
5
3
13
4
3
63
205
150
51
5
166
7
4
6
2
3
4
7
3
3
3
3
6

27
25
24
27
20
30
26
10
17
20
9
23
10
27
39
7
558
233
56
7
106
714
7
7
234
164
9
7
7
9
7
7
35
611
94
39
7
392
8
73
7
30
7
7
7
9
7
9
8
262

RA
RA
RA
RA
RA
RA
RA
Non-RA
RA
RA
Non-RA
RA
Non-RA
RA
RA
Non-RA
RA
RA
RA
Non-RA
RA
RA
Non-RA
Non-RA
RA
RA
Non-RA
Non-RA
Non-RA
Non-RA
Non-RA
Non-RA
RA
RA
RA
RA
Non-RA
RA
Non-RA
RA
Non-RA
RA
Non-RA
Non-RA
Non-RA
Non-RA
Non-RA
Non-RA
Non-RA
RA
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Our Classifications
HDC
HDC
PTM
Peak
Group
group
Ratio
Excuded(abnormal
HPR
run) 0.845
0.702
HPR
0.575
HPR
0.859
HPR
Excuded(abnormal
HPR
run) 0.761
0.942
HPR
1.064
HPR
0.979
HPR
0.757
HPR
0.816
HPR
0.758
HPR
0.761
HPR
0.837
HPR
0.688
HPR
0.750
HPR
0.820
HPR
0.693
HPR
1.025
HPR
0.677
HPR
0.954
HPR
1.341
HPR
1.494
HPR
0.713
HPR
0.610
HPR
1.007
HPR
Excuded(abnormal
HPR
run) 1.017
0.926
HPR
1.038
HPR
1.098
HPR
0.986
HPR
1.087
HPR
0.994
HPR
0.840
HPR
1.204
HPR
1.200
HPR
1.340
HPR
0.926
HPR
0.984
HPR
0.812
HPR
0.670
HPR
0.902
HPR
1.014
HPR
0.660
HPR
1.233
HPR
1.100
HPR
0.790
HPR
0.601
HPR

L3
L3
L3
L3
L3
L3
L1
H4
H4
H4
H4
L1
L3
L3
L3
H4
N/A
L1
L1
L1
H4
L1
L1
L1
L1
L3
L3
H4
L3
H4
L3
H4
L1
H4
L1
L1
L1
L1
H4
L1
H2
H2
H2
H2
H4
H2
H4
H2
H2
H2

As shown in Figure 3A, the non-RA HDCs show a decreased peak ratio (1.00  0.23), and
the RA HDCs show an even more substantial decrease in peak ratio (0.83  0.16). A two-tailed ttest yields a p-value of 0.007 between these two groups, indicating that the HDC peak ratios are
statistically different between RA and non-RA subjects (Figure 3A, 4,5, Supplemental Data 1).
This pattern is consistent with literature and can be seen in other auto-immune disorders such as
lupus (23, 24). Similar to literature (25, 26), when the HDCs were ranked according to peak ratio
(regardless of RA diagnosis), they could be separated into two groups that correlated with the RA
diagnosis: low peak ratio (LPR, peak ratio < 1.00, n = 32), and high peak ratio (HPR, peak ratio >
1.00, n = 15) (Figure 3B). Associating the HPR group with non-RA and the LPR group with RA
gives a point-biserial correlation coefficient of 0.3966, meaning that 39.66% of the variability in
peak ratio can be attributed to the RA diagnosis. With this association, a threshold ratio of 1.00
splits the samples (for the 47 HDCs obtained) with the smallest misclassification rate (27.7%).
Using this threshold, 22 of the 32 samples (68.8%) in the LPR group are classified as RA while
12 of the 15 samples (80.0%) in the HPR groups are classified as non-RA. While 22 of the 27 RA
samples (81.5%) are in the LPR group, and 12 of the 22 non-RA samples (54.5%) are in the HPR
group (Table 1). These classification rates are likely impacted by the imperfect specificity and
sensitivity of RA diagnosis mentioned earlier, as well as the presence of comorbidities in RA and
non-RA subjects.
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Figure 3-DSC results
This study focuses on the two peaks observed between 25 and 100˚C of the heat denaturation
curve. (A) The average HDC curve for non-RA and RA samples, with the difference between the
two shown in black. The first peak from HSA is consistently found around 63°C (low temp peak)
and the second Ig peak is always around 71°C (high temp peak). Inset for A shows the distribution
of peak ratios from the HDC of RA and non-RA subjects. The difference in peak ratio between the
non-RA and RA groups is statistically significant (p = 0.007) (B) The distribution of peak ratio of
all samples, with a peak ratio threshold of 1.00 as the cut-off between the HPR and LPR groups.
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Figure 4- All HDCs per group
It plots the normalized signal vs temperature from raw output. Plots are sorted by RA diagnosis

Figure 5 -Average HDCs with Deviation
It shows the average HDC plot for RA and Non-RA samples, with the shaded region showing the
standard deviation. These two figures are overlayed in Figure 3A.
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Several of the non-RA samples are categorized in the LPR group, and this could be the
result of other diseases or physiological differences (30) that alter HSA and other serum proteins,
such as Lyme Disease, Lupus, or diabetes (22, 43). This seems likely given that all 50 subjects
originally came in for testing because they were experiencing symptoms of discomfort and
sickness. We are interested in mechanisms behind these HDC shifts (Figure 2), so we used MS to
evaluate the differences between both the RA/non-RA subjects and the HPR/LPR groups.

3.4.2 Proteomics
3.4.2.1Protein concentrations
The 50 serum samples were individually digested to tryptic peptides and analyzed using mass
spectrometry to further explore the difference in protein content between RA and non-RA serum
samples. Relative protein quantification analysis (PEAKS Studio_8.5, Bioinformatics Solutions
Inc. (44), Supplemental Data 2) shows there are no significant differences in protein
concentration between RA and non-RA groups or HPR and LPR groups for any of the top eight
most abundant proteins (significant changes are defined as proteins with a fold change less than
0.5 or greater than 2 and a p-value less than 0.05) (Figure 6, Table 2). It is expected that specific
autoantibody concentrations would increase in patients with RA (45–47), but since the RA antigen
specific Ig population is a relatively small percentage of the entire Ig population, and significant
sequence homology exists between immunoglobulins, it is difficult to distinguish target-specific
antibodies using MS only. Also, the comparison was not against "healthy" controls, so that lack of
significance in Ig could likely be because an Ig increase, non-specific to RA, may have occurred
across many of the samples, elevating Ig levels altogether. These results suggest that a change in
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concentration of abundant serum proteins does not contribute to the decreased HDC peak ratio
observed in RA samples.
Table 2-Few Proteins have Significant Changes
RA VS. NON-RA

TOP 8 PROTEINS

.
Protein
Accession
P02768|ALB
U
P0DOX5|IG
G1
P01857|IGH
G1
P01859|IGH
G2
P01860|IGH
G3
P00738|HPT
P0DOX7|IG
K
P02787|TRF
E

Protein Name

Rank

Fold
Change

pValue

Serum Albumin

1

0.96

0.58

IgG Variable 1

2

1.06

0.71

IgG Heavy 1

3

1.05

0.77

IgG Heavy 2

4

1.09

0.56

IgG Heavy 3

5

1.09

0.55

Haptoglobin

6

0.88

0.48

Protein
Accession
P02768|ALB
U
P0DOX5|IG
G1
P01857|IGH
G1
P01859|IGH
G2
P01860|IGH
G3
P00738|HPT
P0DOX7|IG
K
P02787|TRF
E

IgK Light Chain

7

1.26

0.15

Serotransferrin

8

0.85

0.12

Vitamin D
Binding
Protein**

28

0.47

0.04

Melotransferrin

91

0.38

0.03

C-Reactive
Protein*

158

0.45

0.03

P59047|NA
LP5

NACHT

199

0.4

0.01

O94911|ABC
A8

P20936|RAS
A1

Ras GTPaseactivating
protein 1

239

0.41

0.04

Q6MZM0|H
PHL1

P02774|VT
DB
P08582|TRF
M
P02741|CR
P

SIGNIFICANT PROTEINS

LPR VS. HPR

P02741|CRP
P0DJI8|SAA
1
P0DJI9|SAA
2

Q9NXG0|CN
TLN

The 8 most abundance proteins from our MS
analyses are displayed with their associated
fold change and p-value (comparing RA vs.
non-RA and HPR vs. LPR). None of the top
8 proteins are significant in either analysis.
Fold change is dividing RA abundance by
non-RA abundance and LPR abundance by
HPR abundance.
*P02741|CRP_HUMAN (C-reactive protein) is a
known RA biomarker
**Vitamin D is known to be associated with RA

O43395|PRP
F3
P13797|PLS
T
P50993|AT1
A2
Q14789|GO
GB1
P09238|MM
P10
P01699|LV1
44
Q6PGN9|PS
RC1
Q9HCM3|K1
549
Q15459|SF3
A1
P12259|FA5
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Protein Name

Rank

Fold
Change

pValue

Serum Albumin

1

0.96

0.58

IgG Variable 1

2

1.06

0.71

IgG Heavy 1

3

1.05

0.77

IgG Heavy 2

4

1.09

0.56

IgG Heavy 3

5

1.09

0.55

Haptoglobin

6

0.88

0.48

IgK Light Chain

7

1.26

0.15

Serotransferrin

8

0.95

0.65

C-Reactive
Protein*

158

0.48

0.05

160

0.18

0.04

218

0.15

0.04

226

2.03

0.03

Ferroxidase
HEPHL1

245

0.49

0.01

Serum amyloid
A-1 protein
Serum amyloid
A-2 protein
ABC-type
organic anion
transporter

Centlein

254

0.17

0.04

U4/U6 small
nuclear
ribonucleoprotein
Prp3

260

0.18

0.04

Plastin-3

260

0.18

0.04

260

0.18

0.04

260

0.18

0.04

289

2.12

0.03

306

0.35

0.04

316

0.33

0.05

318

0.39

0.04

347

0.18

0.05

355

30.39

0.05

Sodium/potassiu
m-transporting
ATPase subunit
alpha-2
Golgin subfamily
B member 1
Stromelysin-2
Immunoglobulin
lambda variable
1-44
Proline/serinerich coiled-coil
protein 1
UPF0606 protein
Splicing factor
3A subunit 1
Coagulation
factor V

Figure 6-Protein Concentration differences in RA
Volcano plots indicating the fold change and p-value for all 421 detected proteins, comparing A)
RA/Non-RA samples and (B) LPR/HPR samples. The top eight most abundant proteins are
indicated in green (all insignificant), and the statistically significant proteins (-1 > fold change >
1, p-value < 0.05) are indicated in red. C-reactive protein is the only significant protein in both
plots. The fold change is calculated in each comparison by dividing RA abundance by non-RA
abundance and LPR abundance by HPR abundance.

Aside from the top eight proteins, overall proteomic analysis showed that among the 421
proteins compared, a statistically significant two-fold change was only seen in five proteins when
comparing RA to non-RA samples (Figure 6A) and 14 proteins when comparing the HPR and
LPR groups (Figure 6B) The only common significant protein between these two groups was Creactive protein (CRP), a known RA biomarker. The significance of CRP in both the RA vs. NonRA and HPR vs. LPR comparisons indicate that CRP may be involved in mechanisms accounting
for the HDC shift seen in RA samples. It is important to note that CRP concentration is most likely
upregulated for all subjects relative to healthy controls as has been described previously, but it is
significantly lower in both LPR and RA groups. Vitamin D binding protein (VDBP, known to be
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related to RA (11)) was significantly downregulated in RA samples, and had no significant changes
between HPR and LPR groups. These results suggests that although VDBP and other proteins may
be associated with RA, their relatively low concentration means they are not directly affecting the
HDC shift in RA samples. However, the change in the concentration of these proteins may affect
our measurements because they have interactions with the very abundant proteins measured in the
HDC (Figure 2B).

3.4.2.2 Structural changes in high abundance proteins
Since protein concentration doesn’t directly account for the difference in HDCs between
RA and non-RA samples, and there is also no link between concentration and the HPR and LPR
groups. Therefore, we expect, similar to other diseases explored in literature, that the observed
HDC shifts among RA patients and the LPR group are caused by changes in thermal stability for
one of the most abundant serum proteins. We simulated shifts in the melting temperatures of
various percentages of each of the top eight serum proteins (using individually measured HDCs of
these abundant proteins from literature (22)) could recapitulate the observed changes. We found
an increase in the melting temperature for a small fraction (~10%) of the HSA pool could explain
the observed HDC shift (Figure 7). Changes in HSA melting temperature could result from new
ligand binding, protein interactors, or tertiary structure (48–50). Here, we tested for structural
changes of HSA through analysis of covalently modified amino acid profiles between the RA and
non-RA samples. Both biological and artificially induced modifications were considered. Changes
in biological modifications could show altered RA biochemistry, and changes in artificially
induced modifications would show variations in surface accessibility of certain regions of a
protein. If RA-specific protein conformation changes are responsible for changes in the HDCs, we
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also expect these amino acid modification (AAmod) profiles between RA and non-RA groups, to
be correlated with the observed HDC groups (HPR and LPR).

Figure 7-HDC simulation
It uses individually measured HDC of the top 8 proteins in blood serum, simulations were run to
find what type of shift would best fit the difference seen between the HDC in RA and non-RA
samples (black trace in Figure 3A). The best statistical fit was found to be a 10ºC shift in 10% of
the HSA. The "simulated" HDC after the non-RA trace underwent this theoretical shift is shown
by the yellow trace here. Among all of the tested "simulations" (different percentages of the top 8
proteins being shifted by various temperatures), this simulated shift aligned the yellow trace most
accurately with the RA trace. Visual analysis of this plot indicates that it is also likely that a small
percentage of HSA is also shifted by a wider temperature range (some by ~5ºC and some by
~15ºC).

Protein Prospector (UCSF) and PEAKS studio (Bioinformatics Solutions Inc) were both
used for contrasting analysis of the PTM data. Multiple peptide modifications were observed as
noncanonical m/z shifts with Protein Prospector, including a modification of +183 m/z, which was
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the most frequently observed modification (41 peptides) on HSA (Supplemental Data 3). PEAKs
Studio’s analysis of HSA proteins and each AAmod confirmed the +183 m/z modification as an
aminoethylbenzenesulfonylflouride modification (AEBSF) which came from the protease
inhibitor cocktail we added before processing the serum. Thus, AEBSF was an artificially induced,
non-biological PTM. HSA had 185 modified sites that were observed in more than 12 of the
samples. Of the 185 total AAmod sites on HSA, there were 33 observed modification types, with
the top ten most frequent being AEBSF, 41; Dehydration, 28; Hexose, 17; Deamidation, 14;
Iodination, 14; Oxidation, 9; Citrulline, 8; Formylation, 5; Amidation, 5; and Di-iodination, 4. 71%
of these AAmod sites are specific for only one type of modification (Supplemental Data 3).
AEBSF was the only AAmod that showed statistically significant differences between RA and
non-RA groups (Supplemental Data 4). Since the AEBSF modification was synthetically
introduced, it is not causing the change in HSA structure but is reporting the fact that the in vivo
structure was changed for these reactive sites. Non-RA subjects have, on average, 1.9 times more
AEBSF modifications that RA subjects (p = 0.023). Since there were significantly fewer AEBSF
modifications in RA subjects, it suggests that AAmod sites are less accessible in RA HSA,
suggesting conformational changes or a potential increase in binding partners in RA HSA.

3.4.2.3 AEBSF as a probe of surface reactivity
AEBSF is an irreversible serine protease inhibitor which can react with surface accessible
nucleophilic amino acids such as Serine (S), Lysine (K), Tyrosine (Y), Histidine (H), and the
amino-terminus (Figure 8A) (51, 52). Like other good surface modifiers (diethyl pyrocarbonate
(37) or diazonium salt (36)), we can use its prevalence to identify changes in surface area
accessibility of individual amino acids on proteins between samples. The AEBSF modifications
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observed on HSA were most frequently observed on lysine (28 different lysine residues), tyrosine
(9 different residues), serine (2 different residues), and histidine (2 different residues)
(Supplemental Data 4).

Figure 8-AEBSF modification of HSA
(A) The chemical reaction of the AEBSF modification on Serine. The reaction is similar for other
nucleophilic amino acids. (B) The heatmap generated with PNNL Inferno showing the intensity
differences of AEBSF modification at different HSA sites between different samples. The AEBSF
modification amino acid number for HSA is listed on the y-axis, and the serum sample number on
the x-axis. The samples are separated into 4 groups according to the hierarchy branch of serum
samples, from left to right (Supplemental data 4). Group L1 and L3’s AEBSF modifications are
less intense than group H2 and H4 (L stands for lower intensity and H stands for higher intensity).
The three clusters, C1 (green), C2 (purple), and C3 (black), are the most intense AEBSF
modification clusters and are examined to characterize the modification further. (C) The bar graph
shows the number of RA/non-RA and HPR/LPR samples expected in each AEBSF modification
group (L1, H2, L3, H4). The percentage of RA samples in L1, H2, L3, H4, is 73%, 25%, 69%, and
31% respectively. For LPR, it is 67%, 89%, 73%, and 50%, respectively.
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To visualize patterns in AEBSF modification between samples and across AAmod sites,
we used PNNL Inferno (53) to generate a hierarchical grouped heatmap from the patient-specific
ion intensities for each modification site (Figure 8B). From our MS data, samples were sorted into
clusters with serum samples on the horizontal axis and HSA modification sites on the vertical axis.
The hierarchical order separated the samples into 4 groups. Of the 4 groups, two groups have
higher signal intensity (H2 & H4), and two groups have lower signal intensity (L1 & L3). H2 has
higher signal intensity at sites shown in clusters C1 and C2, H4 has higher signal intensity at the
specific sites in cluster C3, and groups L1 and L2 have lower signal intensity across all sites.
Higher signal intensity indicates a greater level of AEBSF modification. Each of these four clusters
(L1, H2, L3, and H4) are made up of 32.6%, 17.4%, 23.9%, and 26.0% of the serum samples,
respectively. Based on the number of samples, the clinical assessment and our HDC results can
anticipate how random assignments would group the samples (null hypothesis, Ho, Figure 8C).
Therefore, we would expect 32.6%, 17.4%, 23.9%, and 26.0% of the samples in each of the
RA/non-RA/HPR/LPR groups to be present in each of these four clusters. As shown in Figure 8C,
we found that a much greater proportion of the RA samples were found in the L1 and L3 groups
(42% and 35%, respectively) compared to the non-RA samples (17% and 17%, respectively). A
lower percentage of RA samples were in the H2 and H4 groups (8% and 15%, respectively)
compared to the non-RA samples (26% and 39%, respectively). The L1 and L3 groups contained
close to the expected proportion of samples from the HPR and LPR groups, but in the H4 group
(containing a high proportion of non-RA samples), we saw a higher-than-expected percentage of
HPR samples (40% of HPR samples were in the H4 group, compared to 19% of LPR samples).
However, in the H2 group (also containing a high proportion of non-RA samples), we saw a higherthan-expected percentage of LPR samples (23% of LPR samples compared to 7% of HPR
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samples). This suggests that the high AEBSF frequency at the AAmod sites in clusters C1 and C2
are connected to a decrease in HDC peak ratio but an RA-negative diagnosis. In fact, more intense
AEBSF modifications at these C1 and C2 sites may give insight into why certain non-RA samples
exhibited a low HDC peak ratio (increased surface accessibility from other factors not specific to
RA). On the other hand, the high AEBSF frequency at the modification sites in clusters C3 are
connected to both a higher HDC peak ratio and non-RA subjects (Figure 8B,8C), indicating that
decreased accessibility of the C3 amino acid binding sites seen in RA samples may be directly
linked to the observed HDC shift seen in RA samples.
Together, this pattern suggesting that HSA in the RA/LPR groups may have binding
partners or other ligand interactors that block those C3 sites. Additionally, the association between
HPR and RA samples in the H2 group suggest that the decreased accessibility of C1/C2 AAmod
sites, likely due to binding partners or other conformational changes, are unlikely to be the cause
of the increased HDC shifts observed in RA HSA. These binding partners could be related to other
diseases that the RA-negative (yet still discomforted) patients were experiencing when they came
in to be tested for RA.
It should be noted that the clustering in our heatmap in Figure 8B is data-driven using
these 50 subjects as a training set. Therefore, statistical inference, error bars, and p-values are not
appropriate as we analyze how the data in Figure 8C deviates from our null hypothesis. To test
the hypothesis that these patterns can be applied to a population with statistical confidence
additional groups of non-RA and RA would need to be collected and compared to our clustered
model. Even without this statistical assessment, previously published literature gives us valuable
insight into these AEBSF groups and the modification sites in relation to specific changes in HSA
tertiary structure.
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3.4.2.4 Potential Binding Surfaces on HSA
The 3-dimensional structure of HSA has three recognized domains, with two subdomains
each (54). There are also nine known binding pockets distributed throughout the three domains.
Two drug binding sites, Sudlow sites I and II are located in domains IIA and IIIA (55, 56),
respectively (Figure 9B). The HSA structure and the AAmod sites for each of the three clusters
was visualized with UCSF Chimera (version 1.15) (57), with C1 sites in blue, C2 sites in red, and
C3 sites in green (Figure 9A). AEBSF modification sites in C1 and C3 are mostly in domain II:
70% and 55%, respectively. AEBSF modification sites in C2 and are mostly in domain I (50%)
(Figure 9C, Supplemental Data 4). Sudlow Site I (IIA) has the most frequently observed (33%)
AEBSF modification sites from all three clusters combined (Figure 9B, Supplemental Data 4).
The modified amino acids in C1 and C3 are mostly lysine, and mostly tyrosine in C2 (Figure 9D,
Supplemental Data 4). PyRosetta (58) was used to extract the secondary structure and surface
accessible surface area (SASA) scores from a representative crystal structure of HSA (PDB ID:
1N5U (59)); 81% of the modification sites are on an α-helix, and 19% are on a loop (Figure 9E,
Supplemental Data 4). The average SASA scores of C1, C2, and C3 are 95.9 ± 37.2, 37.1 ± 32.5,
and 81.8 ± 37.3 (Figure 9F, Supplemental Data 5) where a larger value indicates more surface
accessibility.
When each AEBSF modification intensity is compared between RA and non-RA subjects
in the C1, C2, and C3 clusters, all appear to be less accessible in RA HSA. Statistical analysis
reveals that three C1 sites (Y263, K359, and H367, in subdomain IIB) and two C2 sites (Y401 and
Y497, in subdomain IIIB) have p-values below 0.05, indicating potential RA-specific binding sites
(Table 3, indicated in Figure 9A). These significant sites are labeled in Figure 9A. As explained
for Figure 8C, we do not expect potential binding partners at these C1 and C2 sites to increase
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Figure 9 - Characterizing AEBSF modification site of the 3 clusters (C1, C2, C3) on HAS
(A) A representative HSA crystal structure (PDB ID: 1N5U) with the 3 AEBSF modification sites
clusters colored. The three clusters, C1, C2, and C3 are colored in blue, red, and green,
respectively. Individual C1 and C2 sites that are significantly less accessible in RA HSA are
labeled. The red oval indicates a C3-rich region in domain I that could be a plausible binding site
for RA-specific interactors that most likely to increase HSA stability. (B) The HSA structure is
colored by its 3 domains (I, II, III), and subdomains (A, B). The number of AEBSF modification
sites regardless of cluster designation in each subdomain is listed in parentheses. The 9 known
cargo binding pockets are shown in the gray circles, and the two drug binding sites, Sudlow I &
II, are shown by an arrow. The four bottom-right panels show what percentage of the AEBSF sites
in each cluster (C) is in each HSA domain, (D) is on each amino acid residue, (E) has each
secondary structure, and (F) the average SASA score of each cluster. Only SASA scores between
C1 and C2 are statistically different (p = 0.019).
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HSA thermal stability. This hypothesis is strengthened by the fact that most C1 and C2 sites
(particularly the significant ones) appear on the more outer surfaces of HSA (Figure 9A) and
potentially mobile helices (Figure 9E), making them less likely to have a significant impact on
overall HSA stability. On the other hand, C3 sites appear to be more concentrated to inner folds of
HSA, where a large number of core interactions would need to be broken during denaturation.
Interestingly, no individual C3 sites show statistically significant differences between RA and nonRA groups (Table 3), but as a block there is an enrichment in non-RA subjects with high C3 sites
(Figure 8C). This suggests that the HSA structure is modified by dynamic surface interactors like
other proteins, rather than covalently cross-linked molecules.
The most significantly altered C3 amino acid residue (in terms of surface accessibility) is
S287. Compared to RA subjects, non-RA subjects had 2.54 times has much AEBSF modification
at the S287 site (p = 0.10). In the PDB structure, S287 already appears quite buried in HSA (Figure
9), and its SASA score is only 19.7, the lowest of all C3 sites (Table 3). The next two most altered
C3 sites are K12 and Y452 (near S287) – sites at which non-RA subjects have 1.63 and 1.52 times
as much AEBSF modification (p-values are 0.14 and 0.16, respectively). Seven of the C3 sites
(including these top 3) are in a small, localized area (oval shaped magnification in Figure 9A) in
domain I that could be a plausible binding interface with RA-specific interactors. Binding
interactions could increase thermal stability of HSA and reduce the surface reactivity of these sites.
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Table 3-Each of the AAmod sites for groups C1, C2, and C3
Group
Name

C1

C2

C3

AA

Uniprot
Position

1N5U
position

HSA
Domain

HSA
subdomain

SS

SASA

K
K
K
K
Y
K
H
K
K
K
Y
Y
Y
Y
Y
Y
K
K
K
K
K
K
S
H
K
Y
K

205
229
249
257
287
383
391
402
456
499
108
162
164
377
425
521
36
117
160
214
223
305
311
312
375
476
588

181
205
225
233
263
359
367
378
432
475
84
138
140
353
401
497
12
93
136
190
199
281
287
288
351
452
564

I
II
II
II
II
II
II
II
III
III
I
I
I
II
III
III
I
I
I
II
II
II
II
II
II
III
III

IB
IIA
IIA
IIA
IIA
IIB
IIB
IIB
IIIA
IIIA
IA
IB
IB
IIB
IIIA
IIIA
IA
IA
IB
IIA
IIA
IIA
IIA
IIA
IIB
IIIA
IIIB

H
H
L
H
H
H
H
H
H
H
H
H
H
H
H
L
H
L
H
H
H
L
H
H
H
H
L

62.1
121.2
93.0
79.6
52.4
156.8
72.1
140.5
57.6
124.1
26.2
66.9
5.3
79.9
44.5
139.3
76.1
68.4
131.0
51.6
80.6
19.7
40.0
119.5
88.9
84.2

Fold
Change
(NonRA/RA)
1.70
1.25
2.06
1.30
3.22
1.82
2.19
1.06
1.27
1.56
1.84
1.72
2.19
2.15
3.01
3.34
1.63
1.37
1.48
1.41
1.02
1.29
2.54
1.54
1.42
1.52
1.09

* Sites with statistically significant fold changes between RA and non-RA groups
- Position of this residue in the crystal structure was not resolved in crystal structure
p-value: t-test comparing RA and non-RA site accessibility, using AEBSF signal

pvalue
0.22
0.44
0.09
0.51
0.05
0.05
0.01
0.82
0.38
0.14
0.25
0.24
0.26
0.20
0.05
0.05
0.14
0.31
0.17
0.29
0.95
0.54
0.10
0.46
0.18
0.16
0.81

*
*
*

*
*

3.5 Conclusions
In agreement with literature on other diseases (30, 32), we found that the HDC of serum
are characteristically shifted (shown by a decreased first/second peak ratio) in all subjects
experiencing inflammatory symptoms. Interestingly, RA subjects displayed an even lower peak
ratio compared to non-RA subjects, suggesting a more pronounced HDC shift. In comparison, all
15 of the healthy control subjects used by Garbett et al. (22) fall into the HPR group (peak ratio >
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1.00, Table 4), 54.5% of non-RA subjects, but only 18.5% RA subjects fell into the HPR group.
Our data is consistent with the literature showing that concentrations of the top 8 proteins do not
change significantly during RA or other cases of inflammation (61). Our data supports the
proposed mechanism in Figure 2B, that an increase in HSA stability (5–15ºC increase in melting
temperature for ~10% of HSA) would be a more plausible explanation for difference between nonRA and RA HDCs. CRP, a biomarker known to defend against infectious agents and play a
significant role in the inflammatory response (4, 62), is the only protein with a significantly
different concentration among both comparisons. Both groups are expected to have elevated CRP
concentrations, but relative concentrations are less elevated in both RA and LPR groups, compared
to non-RA and HPR groups. At the same time, we observed that surface reactivity in the C1, C2,
and C3 clusters are less accessible in HSA of RA subjects compared to non-RA subjects, but only
sites in the C3 cluster appear to also be less accessible among the LPR group.
These findings suggest a model consistent with Figure 2B. CRP, produced predominantly
by hepatocytes in response to stimulation by IL-6, is known to be a promiscuous interactor and
recruiter of proteins (63, 64). For example, CRP binding to immunoglobulin Fc gamma receptors
(FcgR) promotes the production of proinflammatory cytokines leading to an amplification loop of
inflammation. (62). It is possible that during inflammation in non-RA subjects, high levels of CRP
associate with HSA binding proteins, sequestering them from HSA. Since CRP is decreased in RA
subjects, these potential HSA interactors would be more available to bind HSA, specifically at the
C3 site surface interface (in domain I of HSA) shown in Figure 6A, increasing HSA stability, and
reducing surface accessibility.
The BioGRID 4.4 interactome database shows 349 known interactors for HSA and 72
interactors for CRP. Three of these proteins are common interactors to both HSA and CRP: 1-
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Table 4-A summary of non-RA and RA subjects versus literature for healthy subjects
Quantitative metric

Healthy (literature)

Non-RA (experimental)

RA (experimental)

HDC ratio

Baseline: 1.59 ± 0.04 (22)

1.00 ± 0.23

0.83 ± 0.16

Peak Ratio Group

100% HPR (22)

54.5% HPR
45.5% LPR

Concentration of top 8
abundant proteins

Baseline, similar to RA and
symptomatic patients (61)

No change compared to RA

18.5% HPR
81.5% LPR
No change compared to
non-RA

CRP concentration

Baseline, low compared to
non-RA and RA (4)

High

Elevated, but lower than
non-RA

More surface reactivity
compared to RA;
significant on sites Y263,
K359, H367

Lower surface reactivity
compared to non-RA;
appears to be associated
with a higher thermal
stability

More surface reactivity
compared to RA;
significance on sites Y401,
Y497

Lower surface reactivity
compared to non-RA;
appears to be associated
with a higher thermal
stability

More surface reactivity,
suggesting a lost binding
interface that exposes K12,
K199, K281, S287, H288, and
Y482

Lower surface reactivity
compared to non-RA;
appears to be associated
with a higher thermal
stability

C1

Binding previously
observed:
K205 (79)
K225 (80)
K233 (81)
K359 (82)
H367 (81)
K378 (81)
K432 (80, 86, 88)
Reactivity previously
observed:
K181 (91), K263 (92),
K475 (91)

C2

Binding previously
observed:
Y84 (83)
Y138 (84, 86)
Y353 (85)
Y401 (86)
Y497 (87)
Reactivity previously
observed:
Y140 (93)

C3

Binding previously
observed:
K12 (80)
K136 (89)
K190 (77, 80, 86)
K199 (77, 80, 86, 88)
K281 (78)
S287 (77)
H288 (90)
K351 (79, 80, 82, 86)
Y452 (88)
Reactivity previously
observed:
K93 (91), K564 (91)
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acylglycerol-3-phosphate O-acyltransferase 1 (AGPAT1), complement factor H (CFH), and
fibronectin 1 (FN1). Some studies have shown brief details about CRP's relationship with
AGPAT1 (65, 66), but extensive studies have shown the specificity and details of CRP's
interactions with CFH (67–70) and FN1 (71–76). The specific location of these proteins'
interactions with HSA is less understood. Nevertheless, most of the C3 modification sites such as
those in the plausible domain I binding pocket (K12, K199, K281, S287, H288, and Y482) are
known to be high affinity binding sites for drugs or other protein interactors (77–90). Table 4
shows which of the C1, C2, and C3 sites have been associated with ligands, drug, or protein
binding sites in previous studies (77–90). For all other sites, reactivity has still been observed (91,
92, 93).
In an effort to better understand RA pathology and potential HSA interactors, future RA
studies should look for potential binding partners by extracting lipids and other cargo from purified
serum HSA. Other directions to explore the mechanisms that increase HSA stability are: (1) Using
more specific surface modifications or chemical crosslinking reagents to carry out more in-depth
surface probing of HSA, allowing more specific information about HSA binding partners and
conformation changes, and (2) comparing HSA and CRP protein binding partners in RA and nonRA patients using immunoaffinity purification together with mass spectrometry to understand how
a relative decrease in CRP could be contributing to HSA protein interactors. Future research into
HSA and other related proteins will continue to enhance our understand RA-specific pathology
and give insights into the development of, and potential treatments for, RA.
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3.6 Methods
3.6.1 Heat Denaturation Curves
50 blood serum samples were taken by ARUP Laboratories to the TA Instruments
application lab.

Samples were prepared in random order for Nano Differential Scanning

Calorimetry DSC measurements by first filtering with a 0.45-micron filter. After being degassed,
40 µL of the blood serum was diluted with 960 µL of buffer. The buffer used for dilution was 10
mM phosphate-buffered saline (PBS) (138 mM NaCl, 2.7 mM KCl at pH 7.50). Samples were
refrigerated at 4 ºC until Nano DSC scans were made. Samples were prepared ten at a time and
loaded into the Nano DSC autosampler at 5 ºC. Samples were scanned from 20 º to 110 ºC at 1
⁰C/min after a 600 second equilibration period after loading. The remainder of the undiluted serum
samples were taken to BYU for MS analysis to look for changes in protein concentration, as well
as PTM frequency and location.

3.6.2 Calculating the Peak Values
Calorimetry experimental results were first corrected for the instrument baseline by
subtracting a buffer injection control. Nonzero baselines were then corrected by applying a linear
baseline fit. Scans were finally normalized for the concentration of protein injected. We then
looked at the raw HDC curve between 25 and 100ºC, setting the minimum of each HDC as 0 and
the maximum as 100. This allowed us to take the peak ratio from two positive values. The first
peak value (HSA peak) was measured at 63ºC, and the second peak value (Ig peak) was measured
at 71ºC. The HSA/Ig peak ratio was then calculated.
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3.6.3 Protein Digestion
The serum samples were denatured with 6M guanidine chloride (GdmCl) in 100mM
Tris/HCl (pH 8.5) and protease inhibitor (Sigma-Aldrich, cat #: P8340), then spun at 21,000xg for
20 minutes at 4 ºC to remove insoluble cell contents. The supernatant, which contains soluble
proteins, was then transferred into new tubes. The BCA assay (Thermo Fisher Scientific cat #:
23227) protocol was followed to measure the protein concentration in each sample. 1.5 µL serum,
which contained about 50 µg of protein, was diluted to 50 µL in 1X PBS, and combined with 100
µL 6 M GdmCl. Each sample was transferred into a new tube, then 1.2 µL of 200 mM dithiothreitol
(DTT, >99% sigma # D-5545) in water was added (final concentration 5mM) and the mixture was
incubated at 55ºC in a sand bath for 15 minutes. The mixture was then cooled for 5 minutes to
reduce disulfide bonding. We then added 3.8 µL of 200 mM freshly made iodoacetamide (IAM,
97% sigma # I-670-9) in water (final concentration 15 mM) and incubated for 1 hour at room
temperature in the dark to alkylate the reduced proteins.
Next, samples were put onto 30 kDa centrifugal filters and spun at 14,000 g for 10 minutes.
Then 100 µL 6M GdmCl in 100mM Tris/HCl (pH 8.5) was added, and the samples were spun at
14,000xg. This was repeated twice. Then 100 µL 25 mM ammonium bicarbonate (ABC) was
added, and the samples were spun again at 14,000 g, this was repeated twice. Next, we emptied
and cleaned the collection tube with ddH2O three times and 100 µL 25 mM ABC was added to the
top of the filter.
MS trypsin (Promega gold MS sequencing grade Trypsin #V5111) was added to the
solution above the filter in a 1:50 (w/w) trypsin/protein ratio and the samples were incubated at
37ºC overnight on a shaker. After that, each sample was quenched with 300 mM
phenylmethylsulfonyl fluoride (PMSF, final concentration 1 mM). Samples were then centrifuged
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at 14,000xg for 30 minutes, 100 µL of 25 mM ABC was added, and the samples centrifuged again
at 14,000 g for 30 minutes. The filtrate was collected in mass spec vials, dried with a Speedvac,
and resuspended in 3% ACN, 0.1% FA to 1 µg/µL.

3.6.4 Mass Spectrometry Acquisition for Proteomics
Data for the 50 samples was acquired in a randomized order. Digested peptides were
separated on a Polaris-HR-C18 HPLC chip in a chip cube nano spray source using an Agilent 1260
HPLC followed by positive ESI and mass detection using an Agilent QTOF mass spectrometer
(6530B). The mobile phases consisted of MS grade 3% acetonitrile, 0.1% formic acid for Buffer
A; and 97% acetonitrile, 0.1% formic acid for Buffer B. A 50-minute gradient was run at
0.3µL/min flow rate: 0%-5% B Buffer (0-0.5 minutes), 5%-30% B Buffer (0.5-27 minutes), 30%95% B buffer (27-28 minutes), 95% B Buffer (28-31 minutes), 95% - 5% B buffer (31 - 33
minutes), 5% - 95% B buffer (33 - 35 minutes), 95% - 0% B buffer (35 – 46 min), 0% B (36-49
min). Auto MS/MS fragmentation using variable collision energy determined by ion mass from
290-1700 m/z at 4 spectra/s rate and 250ms/spectrum time, and with an isolation width around 4
m/z. The auto MS/MS method selected precursor ions that were above 2500 counts and have
charge state 2 and above for fragmentation. MS/MS scan range 100-1700 m/z, and 10 max
processors allowed per cycle. The same spectra were excluded from the MS/MS selection for 0.2
min. This prevented continual acquisition of the same m/z and allowed for other, less abundant
species to be acquired by the mass spectrometer.
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3.6.5 Protein Identification and Quantification
Protein identification and quantification were performed with two programs. The first was
Protein Prospector developed in the University of California San Francisco Mass Spectrometry
Facility, funded by NIH National Institute for General Medical Sciences. The second one was
PEAKs Studio 8.5, developed Bioinformatics Solutions Inc. Both programs compared peptide
fragmentation against the SwissProt human database downloaded in August 2017 with the
following parameters: monoisotopic for precursor mass search type; semispecific for digest mode,
3 missed cleavage allowed; 20 ppm for parent mass error tolerance; 0.5 Da for fragment mass error
tolerance;

3 max variable PTM per peptide allowed, with carbamidomethlyation as fixed

modification, and oxidation, Pyro-glu from Q and other 9 customized PTM as variable
modification (detailed listed in Supplemental Data 3) in PEAKS DataBase step; 311 built-in ptm
was used in the PEAKS PTM step; 20ppm mass error tolerance and 3 min retention time shift
tolerance were used in the label free quantification step. The raw data are available for download
at the chorusporject.org (project ID: 1739, experiment ID:3632).

3.6.6 Protein structure analysis
Some analyses performed with UCSF Chimera, developed by the Resource for
Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with
support from NIH P41-GM103311.

3.6.7 Inferno Hierarchical Clustering and Heatmap analysis
The heatmap for AEBSF on HSA was created using InfernoRDN created by Pacific
Northwest National Laboratory (PNNL, 53). PTM sites were identified and quantified using
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PEAKS Studio. PTM sites that were at least present in 12 samples were included in Heatmap
generation. Files were then loaded into InfernoRDN and Log2 transformed to reduce the noise of
outliers in later analysis. A dual-clustered Heatmap was generated with the standard Euclidean
modeling parameters. The hierarchical order output was then used to determine the most changed
PTM sites between samples and subsequent PTM site groupings. Additionally, the dual-clustering
setting allowed for groups to be observed across samples which were statistically examined for
correlation with RA diagnosis.

3.7 Supporting Information
The following supporting information will be available on the journal website once published
and is available at https://scholarsarchive.byu.edu/data/42.
Supplemental Data 1 (.zip): HDC Results/Simulation
•

The zip file includes 47 HDC results (.csv) exported from DSC raw files. Each HDC
result file contains seven measurements for each DSC run: temperature (°C), power
(µW), time(s), pressure (atm), scan rate (°C/min), analysis data (excess molar heat
capacity (Cpex)), and corrected data (normalized Cpex, normalization explained in the
Methods section).

Supplemental Data 2 (.xlsx): Protein Quantification
•

protein-peptide: the peptide area exported from LFQ from PEAKs Studio for the 49
samples. This is used for protein quantification, and PTM analysis.

•

Filter: The filters applied for LFQ analysis.

Supplemental Data 3 (.xlsx): PTM Results for HSA
•

PTM Results for HSA
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o ProteinProspector: Lists the PTM search result on HSA.
▪

Peptide information: Lists peptide sequence, peptide start position, peptide
end position, peptide theoretical mass, precursor m/z, precursor mass, and
precursor mass.

▪

First/Second Modification: Lists the amino acid, the position, the mass
shift value of the modification, as well as SLIP score (a quality merit of
the modification)

▪

Hit: List if the modified peptide is observed in a sample. If it is present,
the sample name is record in the same row of the peptides. The analysis
only returns present or not, thus PEAKs studio is used for further
quantification.

o Customized PTM search: Lists the name, m/z shift, modified AA for the PTM
put in the database search step of PEAKs studio analysis.
o Albu_ptm profile: The data from PTM profile of PEAKs Studio SPIDER
analysis. It lists all PTM observed on HSA, and the modification site. The peptide
sequence window, the modified amino acid (AA), the occurrence of the same
modified AA in the dataset, the modified site on the protein, the occurrence of the
same modified site in the dataset, best-10logP, best ion intensity (%), and number
of hit across 49 samples.
Supplemental Data 4 (.xlsx): AEBSF sites on HSA
•

T-test: Lists t-test results between RA and non-RA subjects, as well HPR and LPR
subjects, showing significance between RA and non-RA subjects in each comparison.
The average intensity of the sum of all of AEBSF modification sites on HSA of each
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sample, for RA and non-RA, as well as HPR and LPR, is shown. A t-test was also
performed between groups for modification sites in clusters 1, 2, and 3.
•

AEBSF_HSA (site): This dataset lists the structure characteristic of the 41 AEBSF sites
on HSA, including association with the cluster groups from Figure 4B, HC order from
Inferno, site position from Uniprot, site position from PDB ID 1N5U, HSA domain, HSA
subdomain, amino acid (AA), secondary structure (SS), surface accessible surface area
(SASA) score, number of peptides used for the quantification of the site, peptide
sequence, and the intensity from each sample. (The intensity here used the area from
supplemental data 3. Only peptides from HSA and with AEBSF modifications are
retained. The area of peptides that have same AEBSF modification site are combined (the
number of peptides is used for combination is listed in column #peptide combined). After
consolidation, site that have less than 12 hits are removed. Note that the
sequence/start/end for sites that used more than 1 peptides are just representative. The
intensity is also used for Inferno analysis).
AEBSF_HSA_(cluster site) : A list of all samples, with their groups (RA/non-RA and
HPR/LPR), as well as the intensity sum of AEBSF modification for each modification
site in cluster C1, C2, C3 on HSA.

Supplemental Information (.docx) MS2 spectra for PTM on HSA

3.8 Abbreviations:
AAmod: amino acid modification,
ABC: ammonium bicarbonate,
ACPA: anti-citrullinated peptide antibodies,
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AEBSF: aminoethylbenzenesulfonylflouride,
AKA: anti-keratin antibody,
ARUP: Associated Regional and University Pathologists,
CCP: cyclic citrullinated peptide,
CRP: C-reactive protein,
DSC: Differential scanning calorimetry,
DTT: dithiothreitol,
GdmCl: guanidine chloride,
HAPT: Haptoglobin, Ig: Immunoglobulin,
HDC: Heat Denaturation Curves,
HDL: high-density lipoprotein,
HPR: high peak ratio,
HSA: human serum albumin,
IAM: Iodoacetamide,
LC–MS/MS: Liquid chromatography–tandem mass spectrometry,
LPR: low peak ratio,
MS: mass spectrometry,
PBS: phosphate-buffered saline,
PMSF: phenylmethylsulfonyl fluoride,
PNNL: Pacific Northwest National Laboratory,
PTM: post translational modification,
QTOF: Quadrupole Time-of-Flight,
RA: rheumatoid arthritis,
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RF: rheumatoid factor,
SASA: surface accessible surface area,
VDBP: Vitamin D binding protein,
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CHAPTER 4: QUANTIFYING IN SITU STRUCTURAL STABILITIES OF HUMAN
BLOOD PLASMA PROTEINS USING A NOVEL IODINATION PROTEIN STABILITY
ASSAY (IPSA)

4.1 Chapter Summary
This chapter introduces a novel assay, Iodination Protein Stability Assay (IPSA). IPSA is
used to quantify protein quality by measuring protein folding stability. To our best knowledge,
this is the first in situ study that measures the protein folding stability of proteins from human
serum. We confirmed that IPSA is sensitive to measuring the differences in protein folding
stability between transferrin’s different iron-binding states. Besides some grammar corrections
and the difference in the numbering of figures and supplemental data, the content is mostly
identical to the primary research manuscript submitted to the Journal of Proteome Research in
June 2022.

4.1.1 Authors in Order of Contribution
Hsien-Jung L. Lin, Isabella James, Chad D. Hyer, Connor T. Haderlie, Michael J.
Zackrison, Tyler M. Bateman, Monica Berg, Ji-Sun Park, S. Anisha Daley, Nathan R. Zuniga
Pina, Yi-Jie J. Tseng, James D. Moody, John C. Price

4.1.2 Contributions of Major Authors
This project represents most of my graduate journey in searching for the best assay to
quantify proteome quality. When I first started, our lab was already an expert in protein turnover.
I was given the task of completing the kinetic protein homeostasis model with the tool to measure
protein folding stability. Since there was no publicly available program to generate denature
curves, my first task was writing the code to process data and calculate the denature midpoint of
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each measured peptide. The code I wrote became the base code for our in-house program, CHALF.
After recognizing the currently available stability assays don’t fit our needs to measure serum
proteins that have only a few methionines, I started developing a new assay so we could make
measurements. I tried multiple modifiers that can covalently modify different amino acids at the
reporter for surface accessibility before settling with molecular iodine. I was also in charge of the
development of MS acquisition methods. I performed most of the experiments during the
development stage. Later, I was blessed to have many talented students working on my team. I
trained them myself to make sure they could replicate all my wet lab skills and know all the details
about the assay. Since then, these talented students have become my hands. We were able to speed
up the progress because of many students’ hard work. I didn’t personally perform the wet lab
portions of the experiments presented in this paper. However, I was the one to coordinate and
supervise all aspects of the work, including experimental design, giving instructions on software
design, time management, running samples on MS, data validation, troubleshooting, and the
majority of data analysis and manuscript writing. The experiments used in this particular paper
were mainly performed by Isabella James, and Chad D. Hyer had made the greatest contributions
to the development of the in-house program CHALF and statistical validation.
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4.2 Abstract
Many of the diseases that plague society today are driven by a loss of protein quality. One
method to quantify protein quality is to measure the protein folding stability (PFS). Here we
present a novel mass spectrometry (MS)-based approach for PFS measurement, Iodination Protein
Stability Assay (IPSA). IPSA monitors the surface accessibility differences of tyrosine, histidine,
methionine, and cysteine under denaturing conditions. Relative to current methods, IPSA increases
protein coverage and granularity to track PFS changes of a protein along its sequence. To our
knowledge, this study is the first time the PFS of human serum proteins have been measured in the
context of the blood serum (in situ). We show that IPSA can quantify PFS differences between
different transferrin iron-binding states in near in vivo conditions. We also show that the direction
of the denaturation curve reflects the in vivo surface accessibility of the amino acid residue and is
correlated to PFS. Along with IPSA, we introduce an analysis tool CHALF, that provides a simple
workflow to calculate the residue stability. The introduction of IPSA increases the potential to use
protein structural quality as a metric in understanding the etiology and progression of human
disease.

Key word: protein stability, protein folding stability, ligand-binding (iron), Transferrin,
proteostasis, structural correlation, human blood serum measurement, TMT multiplexing
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4.3. Introduction
Currently, most diagnosis and biomarker studies focus on changes in concentration in
proteins or other biomolecules due to disease or drug administration. However, concentration is
not sufficient to assess whether a given protein is active and influencing patient health. Proteins
need to maintain specific structures in order to perform their designated functions. There is a need
to quantify the folding quality of the proteins in the proteome to understand disease mechanisms
and promote earlier and/or more effective treatments. The quality of individual proteins can be
evaluated in part using protein folding stability ( G folding) as a quantifiable metric of protein
structure, which is directly related to their 3-dimensional structure and functionality1-6. However,
it becomes difficult to correct or degrade any misfolded species if they become too stable and form
amyloid or aggregate, as is the case for many neurodegenerative diseases7-9. A change in protein
folding stability (PFS) between conditions may indicate an individual protein’s tendency for
proper function (stable2), misfolding (less stable2), and aggregation (ultra-stable2), and thus
quantify the quality of the measured protein10. Ideally, such measurement should be made for each
protein in the context of the entire proteome to retain the effect from the interactions with other
proteins and ligands. However, the experimental techniques available currently limit studies of
PFS on the proteome level.
The PFS is traditionally measured by circular dichroism (CD) spectroscopy or thermal shift
assay (ThermoFluor), which has been well defined experimentally and has good time resolution.
The limitation for both CD and ThermoFluor is that they require purified proteins and cannot
therefore be run under physiological conditions11-12. Multiple Mass Spectrometry (MS)-based
methods allow measurement of proteins in complex mixtures and retain the proteins’ information
under physiological conditions. Thermal denaturation methods, such as TPP (Thermal Proteome
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Profiling) and LiP (Limited Proteolysis) allow for proteome-wide measurements but calculate only
the average stability of the entire protein or the domains of a protein; information about individual
residues across the protein sequence is lost13. Moreover, it is difficult to apply thermal denaturation
methods on blood serum, the most common biological source for diagnosis. This is because serum
albumin (HSA), the most abundant serum protein, has a relatively high melting temperature14, 15
and thus reduces the efficiency of the temperature gradient to aggregate the proteins using thermal
cyclers currently commercially available 10, 16. Removing HSA prior to thermal denaturation is not
a viable answer as that may alter many other proteins’ PFS because HSA also stabilizes many
serum proteins. Chemical modification methods can measure the PFS of different residues across
the protein sequence, but are also highly sequence dependent. For example, the SPROX
(stability of proteins from rates of oxidation) uses oxidized methionine as reporter17, 18. However,
proteins may have few methionines, which limits the sequence coverage of any individual protein,
and which makes it a challenge to measure domain specific information. Hydrogen-deuterium
exchange can provide stability information at every residue of the protein, but the deuterium
modifications are exchangeable and therefore not amenable to sample fractionation strategies19.
So although current methods have provided important insights into protein structure and stability,
there are difficulties applying them to blood serum.
To address the limitations mentioned above, we modified the traditional chemical
denaturation method by using iodine to modify amino acid sidechains. We termed this assay IPSA,
Iodination Protein Stability Assay (Figure 1A). IPSA introduces irreversible iodination of tyrosine
(Y), and histidine (H); as well as oxidation of methionine (M) and cystine (C) (Figure1B). The
additional reporters for PFS given by IPSA increase both the breadth of the proteome and the
granularity of information within individual proteins10. The biggest advantage of IPSA is that it
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quantifies residue stability, which gives higher resolution to track the PFS change within different
regions of a protein. We and others observe that PFS can vary between different domains within
the same protein20. Greater reporter density allows more measurements around ligand binding at
specific sites. We also introduce a user-friendly analysis tool CHALF, to calculate the residue
stability. In the analysis normalized peptide area from different [GdmCl] is fit into a denaturation
curve, and the denature midpoint (C1/2) of each peptide is calculated (Figure 1C). The C1/2 of
peptides that share the same label site and label type are then combined to calculate the site C 1/2.
The site-specific C1/2 values from the same protein are then plotted (Figure 1D) across the protein
sequence to compare domain specific changes with other conditions. Using IPSA, we are able to
study the residue specific structural details including surface accessibility and domain-specific
folding stability.
This study applied IPSA to undepleted human serum from a healthy subject to show that
IPSA is capable of reproducibly measuring PFS of proteins in the complex mixture of blood serum
at near physiological conditions. We quantified assay efficiency and reproducibility and provide a
survey of the top proteins in the serum proteome. We observed that the slope of each denaturation
curve is a metric of the amino acid surface exposure in vivo and discuss how PFS is related to the
structural information extracted from x-ray crystallography. We then compare the PFS of the
transferrin protein in serum versus purified forms for two different iron binding states. Lastly, we
discuss the variation of C1/2 and structural parameters of different binding status of transferrin. This
study is the first, to the best of our knowledge, that measures PFS of human serum proteome. It
emphasizes the potential of using PFS to quantify protein folding changes in situ, and lays the
foundation for future application of the IPSA technique.
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Figure 1-IPSA Workflow
(A) A gradient of GdmCl from 0M to 6M is added to aliquots of a sample unfolding each type of
protein within the mixture to different degree. Then iodine solution is added to each aliquot to
modify surface exposed Y, H, M, and C. After quenching, each aliquot is subjected to standard
proteomic workflow: denaturation, reduction, alkylation, digestion, LC/MSMS acquisition,
identification for protein/peptide/post-translational modification, and quantification. The
quantification results are input to CHalf to obtain C1/2 value and slope direction. (B) The chemistry
reaction of iodination on Y and H, and the oxidation on M and C due to the addition of iodine
solution. (C)The CHalf graphical output of the denaturation curve for each peptide. Normalized
area of a given peptide from 3 replications are used for generating one denaturation curve and
the denature midpoint (C1/2) value. The fitting statistic identifies outliers (outside the standard
error range) which are trimmed for a final C1/2 value and confidence interval at 95% calculation.
On the left is an example of denaturation curve that has positive slope, and the curve on the right
has negative slope. (D) Sample C1/2 vs Residue number plot of individual protein which is used to
visualize the PFS changes a cross the protein sequence between different experimental condition.
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4.4 Experimental Procedure
4.4.1 Samples Source And Experiment
Serum sample used was collected at BYU from a single healthy subject (BYU
IRB#F17175), and serum protein concentration was measured using BCA protein assay (Thermo
Fisher #23225). The use of a single subject was to minimize the biological variability and focus
on the characterization of IPSA. Purified apo transferrin (apoTF) and holo transferrin (holoTF)
were purchased from Lee Biosolutions, dissolved at a concentration of 10 mg/mL in 50mM tris
pH 7.4. All protein samples were aliquoted into a volume that contained sufficient protein to
generate one full denaturation curve (to avoid freeze/thaw cycles and minimize any alterations in
protein structure) and stored at -80oC before use.
There were 3 samples, purified iron-free transferrin (apoTF), purified iron-saturated
transferrin (holoTF), and native serum. For each of the sample sources, three independent
replicates were prepared and subjected to IPSA and protein digestion. Half of the serum sample
from each process replicate was subjected to TMT multiplexing after digestion. ApoTF and
holoTF were run label free on Agilent 6560 IM-QTOF without ion mobility separation. Serum
samples that did not undergo TMT multiplexing were run label free on both the Agilent 6560 IMQTOF (serum QTOF-LFQ) and a Thermo Fusion Lumos Orbitrap (serum Orbi-LFQ). Serum
samples that have TMT multiplexing were run on a Thermo Fusion Lumos Orbitrap (serum OrbiTMT).
All samples and data types were used in the efficiency and reproducibility analysis. Serum
QTOF-LFQ is used for slope analysis, IPSA application on serum and transferrin, and C 1/2’s
correlation to structural parameters. ApoTF and holoTF are used for IPSA application on
transferrin.
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4.4.2 Iodine Protein Stability Assay (IPSA)
Generally, protein homogenate was diluted to 10 μg/μL and aliquoted into fractions. Each
fraction was unfolded to a different degree with an increasing concentration of Guanidinium
chloride (GdmCl in 50mM tris, pH 7.4) gradient at a constant volume ratio for 30 minutes at 37°C:
native state at 0M and most unfolded at the highest [GdmCl] (>6M). The iodination step was
modified from Huntley et al21: 2μL of 150mM I2 (Alfa Aesar, Cat# 41955) in 600mM aqueous
KI (Fisher Scientific, Cat# 5324-100) making the KI3 reagent. The expected structure of each
modification is shown in Figure 1B. The reaction is quenched by addition of 50mM imidazole
(final concentration).
For apoTF and holoTF experiments, 900μg of 10 μg/μL purified protein was aliquoted into
9 fractions and incubated with 13.8μL of 0M, 0.75M, 1.5M, 2.25M, 3M, 3.75M, 4.5M, 5.25M,
and 6M stock GdmCl. After the 30 minute incubation at 37°C , 2μL 125mM KI3 was then added
and allowed to react for 10 minutes followed by 25μL of 100mM imidazole to quench. For serum
experiments, 2000μg of serum protein was aliquoted into 10 fractions, and incubated with 27.6μL
of 0M, 0.75M, 1.5M, 2.25M, 3M, 3.75M, 4.5M, 5.25M, 6M, and 6.2M of stock GdmCl. After the
30 minute incubation at 37°C, 2μL 150mM KI3 was added and allowed to react at 37°C. After 10
minutes, 50μL of 100mM imidazole was added to quench the reaction.

4.4.3 Protein Digestion
After IPSA, 200μL 6M guanidine hydrochloride, 9 μL of 250mM Tris(2carboxyethyl)phosphine hydrochloride (TCEP, final concentration 10mM), and 36μL of 250mM
2-chloroacetamide (CAA, final concentration 40mM) was added to denature, reduce, and alkylate
the protein solution. This mixture was then heated at 98°C for 5 minutes, followed by 5 minutes
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of sonication, and then transferred to a 30kDa spin filter and spun for 15 min at 14,000xG to
remove salts. The protein was washed twice with 200μL of 25mM ammonium bicarbonate (ABC)
and then spun at 14,000 xg for 15 minutes. Filtrate was discarded. The protein was then digested
in 300μL of 25mM ABC overnight with 4μL of 1μg/μL LCMS grade trypsin protease (Pierce,
Cat#90058) in 50mM Acetic Acid, and incubated at 37°C with shaking overnight. The digested
peptides were collected by spinning at 14,000xG for 15 minutes, adding another 100μL of 25mM
ABC, then spinning again at 14,000xG for 15 minutes. The filtrate containing the digested peptides
was dried in a SpeedVac concentrator (SAVANT SPD131DDA), and then resuspended in 0.1%
Formic Acid in 3% Acetonitrile. The samples were then stored at -20°C before MS acquisition.

4.4.4 TMT Multiplexing
For the Serum Orbi-TMT experiment, we labeled each of the ten samples in the
denaturation curve with a different channel from TMT10plex (Thermo Fisher #90111) following
the scale down protocol from Zecha et al22, and then combined the channels into one sample for
each denaturation curve. Specifically, 50μg of digested peptide from each [GdnHCL] sample were
placed in screw cap vials, dried, and resuspended in 10μL 100mM TEAB pH 8.5 to reach 5μg/μL
concentration. The TMT reagent vials were equilibrated to room temperature and dissolved in
100% Acetonitrile (LCMS grade). Each TMT reagent vial was opened and dissolved in ACN
immediately before the TMT solution was added to the samples. After 1 equivalent of TMT was
added, samples were incubated at room temperature for 1 hour with shaking. Following incubation,
1μL 5% hydroxylamine was added to each sample to quench the reaction, and samples were then
incubated for 15 minutes at room temperature. For each denaturation curve, the entire TMTlabeled volume was then combined into one tube and speed vac to dry. Unused TMT solution was
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dried under argon and then stored under argon at -80C. The dried peptides were resuspended in
300μL 0.1% TFA for desalting. Peptide desalting spin columns (Thermo Fisher #89851) were
placed into low protein-binding 2mL microcentrifuge tubes and spun at 5000xg for 1 minute. The
columns were washed twice with ACN and twice with 0.1% TFA, at 5000xg for 1 minute for each
wash. The samples were then added to the columns, which were then spun for 1 minute at 3000xg.
This was followed by three washes of 300μL 0.1% TFA at 3000xg for 1 minute each. Next, the
column was washed twice with 300μL 5% MeOH, 0.1% TFA for 1 minute each at 3000xg. The
peptides were eluted using 50% ACN, 0.1% TFA. The peptides were dried and then resuspended
to 0.1% Formic Acid, 3% Acetonitrile and stored at -20°C until MS acquisition.

4.4.5 LCMS/MS Acquisition
Three different mass spectrometric acquisition methods were used primarily based on the
experiment condition. Agilent 6560-LFQ method was used for apoTF, holoTF, and serum
QTOF-LFQ, Thermo Lumos-LFQ method was used for serum Orbi-LFQ, and Thermo LumosMS3 method was used for serum Orbi-TMT. All the MS raw files are available for download at
the chorusporject.org (project ID:1771, experiment ID:3683,3684,3685,3686,3687).

4.4.5.1 Agilent 6560-LFQ method
Digested peptides were separated on a Luna Omega 1.6 µM Polar C18 100Å LC Column,
150*2.1mm (Phenomenex, cat #AJ0-9502), coupled with a C18 security guard cartridge
(Phenomenex, cat #00F-4742-AN) using the Agilent 1290 Infinity II LC system and then analyzed
with Agilent 6560 Ion Mobility QTOF without active IM. 40μg of peptide in 10μL were eluted
with a mixture of solvent A (LCMS grade 0.1% Formic Acid, 3% Acetonitrile in Water) and
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solvent B (0.1% Formic Acid, 80% Acetonitrile) at a flow rate of 0.3mL/min for 60 minutes. The
linear gradient applied was 0-5% solvent B for 12 seconds, 5-40% solvent B for 40 minutes, 40100% solvent B for 5 minutes, and 100% solvent B for 10 minutes. There were two 5-minute
seesaw washes from 100%-0% at the end.
Peptides were electrosprayed at 3000V with a Dual AJS ESI Source. The gas temperature
was 325°C, the drying gas flow rate was 5 l/min, and nebulizer pressure was 40psi. The sheath gas
temperature was 275°C, with flow rate 8 l/min. The mass spectrometer was operated in auto
ms/ms, positive ion, and QTOF only mode. The precursor ion (MS1) and fragmented ion both had
a scan range from 100-1700 m/z, with scan rate 3 spectra/s, and medium (~4 amu) isolation width.
The formula 3.6*m/z / 100-3 was used for collision energy. Precursor ions that were above 10,000
counts, and had charge states +2 and above were isolated for MS2. Active exclusion was enabled
to exclude after 2 spectra, and release after 1 min. A maximum of 6 precursors were allowed per
cycle, and the mass tolerance was set at 20ppm.

4.4.5.2 Thermo Lumos-LFQ method
Digested peptides were separated on a C18 Easy-Spray analytical column with 2um
particle size, 100Å pore size, 75uM diameter and 250mm length (Thermo PN ES902), coupled
with a C18 precolumn, with 5um particle size, 100Å pore size, 300uM diameter and 5mm length
C18 (Thermo PN160454) using the Thermo Utlimate 3000 LC system and then analyzed with
Thermo Fusion Lumos Orbitrap. 2μg of peptide in 1μL were eluted with a mixture of solvent A
(LCMS grade 0.1% Formic Acid, 3% Acetonitrile in Water) and solvent B (0.1% Formic Acid,
80% Acetonitrile) at a flow rate of 0.3μL/min for 144 minutes. The linear gradient was held at 5%
solvent for 2 minutes, 5-22% solvent B for 85 minutes, 22-32% solvent B for 15 minutes, 32-95%
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solvent B for 10 minutes, and held at 95% solvent B for 10 minutes. The last 22 minutes included
two seesaw washes from 100-0% .
Peptides were electrosprayed using a EasySpray NSI source in positive mode. The voltage
started from 1200V at 0 minutes, was increased stepwise to 2400V at 3 minute, and held at 2400V
untill 144 minutes. The ion transfer tube was set at 275°C. The cycle time was 3 seconds. MS1
was detected in the orbitrap at 120,000 resolution (FWHM) with scan range from 375-1700 m/z,
maximum injection times of 50ms, AGC at 400,000, and RF lens at 30%. MS1 precursors that
were above 5,000 intensity threshold and with a charge stage between 2-6 were allowed for MS2
fragmentation. The dynamic exclusion was set to 60 s after 1 occurrence and with 10 ppm mass
tolerance. The isotopes were also excluded from MS/MS fragmentation. Precursors were
fragmented using CID mode with collision energy set at 30%, activation time set at 10ms, and
isolation window set at 1.6 m/z. MS2 spectra were detected in ion trap using DDA mode, with
scan rate set at normal, maximum injection time set at 35ms, and AGC target set at 100,000.

4.4.5.3 Thermo Lumos-MS3 method
Digested peptides were separated on a C18 Easy-Spray analytical column with 2um
particle size, 100Å pore size, 75uM diameter and 250mm length (Thermo PN ES902), coupled
with a C18 precolumn, with 5um particle size, 100Å pore size, 300uM diameter and 5mm length
C18 (Thermo PN160454) using the Thermo Ultimate 3000 LC system and then analyzed with
Thermo Fusion Lumos Orbitrap. 2μg of peptide in 1μL were eluted with a mixture of solvent A
(LCMS grade 0.1% Formic Acid, 3% Acetonitrile in Water) and solvent B (0.1% Formic Acid,
80% Acetonitrile) at a flow rate of 0.3μL/min for 144 minutes. The linear gradient applied was
held at 5% solvent for 1.5 minutes, 5-22% solvent B for 63.5 minutes, 22-52% solvent B for 35
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minutes, 52-95% solvent B for 10 minutes, and held at 95% solvent B for 10 minutes. The last 22
minutes included two seesaw washes from 100-0% .
Peptides were electrosprayed using an EasySpray NSI source in positive mode. The voltage
started from 1200V at 0 minutes, increased stepwise to 2400V at 3 minute, and held at 2400V till
90 minutes. The ion transfer tube was set at 275°C. The cycle time was 3 seconds. MS1 was
detected in the orbitrap at 120,000 resolutions (FWHM) with scan range from 360-1700 m/z,
maximum injection times of 50ms, AGC at 400,000, and RF lens at 30%. Precursors that were
above 5,000 intensity threshold and with a charge stage between 2-6 were allowed for MS2
fragmentation. The dynamic exclusion was set to 45 s after 1 occurrence and with 10 ppm mass
tolerance. The isotopes were also excluded from MS/MS fragmentation. Precursors were
fragmented using HCD mode with collision energy set at 35%, activation time set at 10ms, and
isolation window set at 0.7 m/z. MS2 spectra were detected in ion trap using DDA mode, with
scan rate set at normal, maximum injection time set at auto, and AGC target set at 100,000. MS2
detection was followed by SPS MS3 acquisition with 10 notches23. The resolution of SPS MS3
was set at 50,000, and with scan range from 100 to 500 m/z. MS2 precursors were fragmented
using HCD mode with collision energy set at 55%, and detected in the orbitrap. The maximum
injection time was set at 86ms, isolation window was set at 2.5 m/z, and AGC target was set at
250,000.

4.4.6 Data Processing
4.4.6.1 Identification and Quantification
The peptides, proteins, and TMT modification were identified and quantified using PEAKs
Studio 10.6 (Bioinformatics Solution Inc.). Raw files from the same denaturation curve were
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analyzed in the same project as individual samples. The data refinement was set to use the correct
precursor and mass only. De novo peptides were searched against a uniport homo sapiens database
(downloaded in October 2020) with precursor mass tolerance at 20 ppm (monoisotopic) and
fragment ion mass tolerance at 0.5Da. Trypsin was the enzyme, with digestion mode set at
unspecific, and 3 missed cleavages allowed per peptide. 11 PTMs were included in the search:
Carbamidomethylation (C (+57.02)) as a fixed PTM; Pyro-glu from Q (Q (-17.03)), Iodination
(HY(+125.90)), Di-Iodination (HY(+251.79)), Oxidation (M(+15.99)), Sulphone (M(31.99)),
Sulfenoic Acid (C(+15.99)), Sulfinoic Acid(C(+31.99)), and Sulfonoic Acid (C(+47.98)) as
variable PTMs. TMT-10plex (+228) was added as a fixed PTM for TMT samples. The FDR was
set at 1% for peptide and proteins. For LFQ, the quantification was run with 20 ppm mass error
tolerance, and a 3 minutes retention time shift tolerance. For TMT, reporter ion quantification was
run with MS3 as reporter ion type, mass error tolerance set at 0.5 DA, FDR threshold set at 1%.
Prior to exporting quantification results, the filters were all turned off. The LFQ result was
normalized to TIC and auto normalization was applied to TMT the result.

4.4.6.2 C1/2 Calculation
The denatured midpoint (C1/2) is the GdmCl concentration where the native and unfolded
protein are in 1 to 1 ratio24 . The C1/2 represents the resistance of the protein to the denaturation
caused by GdmCl and is proportional to ∆G unfolding (∆G˚unfolding = -m * C1/2) 18 . A higher C1/2
value indicates a more stable area of the protein. Quantification results exported from PEAKS
Studio

were

imported

to

CHALF,

our

data

processing

tool

(https://github.com/JC-

Price/Chalf_public/releases/tag/CHalf_v4.2.1). Using CHALF, the denature midpoint (C1/2) of each
peptide was solved by fitting the normalized signal intensity into a sigmoid curve using Equation 118.
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𝒚=𝑨+

(𝑩−𝑨)
1

− (𝑪
−x)
𝟏+𝒆 𝑏 𝟏/𝟐

(Equation 1)

The peptide-specific parameters for the equation were normalized signal intensity in each
fraction (y), final GdmCl concentration of each fraction (x), pre-transition baseline (A), posttransition baseline (B), denature midpoint (C1/2), and the slope of transition respectively (b). After
an initial regression, the program excluded outliers outside the range of standard error, and
performed the regression for each peptide for the second time. After data filtration, the peptides
that share the same modification site in the protein were all compiled into one set and undergo
regression. The C1/2 resulting from this regression was then the C1/2 of the individual residue. The
data filters applied to identify high quality sites are: C1/2 in the range of measurement (0 - 3.48M),
R2>0.6, and confidence interval < 1/3 of the measurement range.
For assay efficiency and reproducibility analysis, each replication from the same
experimental condition was considered as an individual condition and fit separately in CHALF. For
denaturation curve slope analysis, assay application, and correlation with X-Ray Crystallography
structures, all replicates from the same experimental condition were combined to generate a single
regression. A dermal fibroblast data set was used as the SPROX literature comparison since no
published serum data are available using SPROX. Raw data (Bio1_Tech1B/2B/3B_fraction1-817)
were downloaded from the PRIDE partner repository (dataset identifier PXD011456), and
subjected to the same data analysis flow as the IPSA experiments.
4.4.6.3 Structure parameter extraction
Site-specific C1/2 from serum QTOF-LFQ experiments were compared with X-Ray
Crystallography structure parameters (secondary structure (SS), solvent accessible surface area
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(SASA), Rosetta energy unit (REU), and b-factor) extracted using protein_info_extract.py
(https://github.com/JC-Price/Chalf_public/releases/tag/Protein_Info_Extractor).

PyRosetta25

utilizes cleaned protein PDB files (without non-protein molecules). If a protein’s small-molecule
ligand is not parameterized in the PyRosetta database, it will automatically discard it. Secondary
structures were assigned based on the Dictionary of Secondary Structures of Proteins (DSSP) 26
algorithm by recognizing hydrogen bonding patterns extrapolated from the atomic coordinates of
the input PDB files.
The solvent accessible surface area (SASA) of each amino acid residue was calculated
using the Lee-Richards molecular surface27, 28. The total residue energy (Rosetta energy unit,
REU) of each residue based on the Rosetta score function (energy function is used as the default
score function) 29, 30. Though the REU was not created to be interchangeable with actual physical
energy units (kcal/mol or kJ/mol), the nature of the REU is similar to Gibbs free energy. In other
words, a low REU represents a possible native-like protein conformation and thermodynamic
stability 29-31. The b-factor of each residue is an experimental value known to be the indicator of
mobility and dynamics of individual atoms or sidechains. A large b-factor reflects higher flexibility
of the atoms and sidechains32.

4.5 Result
4.5.1 Efficiency
It should be noted that the huge range of protein concentration in the serum may have
limited the total number of peptides useful for the IPSA efficiency and analytical assessments, thus
the percentages of detected peptides are the most comparable metric versus the cultured cell data
used for SPROX efficiency. For fitting efficiency, we calculated the number of modified amino
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acid sites that have C1/2 values that pass through several filters. The filters were: C1/2 in the range
of measurement (0-3.48M), R2>0.6, and confidence interval < 1/3 of the measurement range.
(Figure 2B, Supporting Data 1).

Figure 2-Efficiency
The efficiency comparison between IPSA data (serum QTOF-LFQ) (blue) and SPROX data
(HCA2-hTert, Orbi-TMT) (orange) (A) Label Efficiency is the percentage of the number of
peptides that have a modified amino acid relative to the total number of peptides with that amino
acid. The first two columns are the overall label efficiency at protein and peptide level, and the
rest are the label efficiency of each label type. (B) Fitting efficiency is the percentage of the number
of high quality C1/2 site to the number of peptide that can be fit. The first column is the overall
fitting efficiency at peptide level. The rest of the columns are the label type break down from the
high quality C1/2 site in the first column. (C) The first column is the overall fitting efficiency at
protein level. The rest of columns show the percentage of protein population that have multiple
C1/2 sites measured per protein.

In order to optimize the iodine incubation, we monitored the percentage of each amino acid
that becomes modified during the incubation while minimizing off target effects. The current
version of IPSA has label efficiency 27.64%  0.43% for Y(+125.90), 15.73%  0.29% for
Y(+251.79), 15.13%  0.81% for H(+125.90), 0.68%  0.91% for H(+251.79), 12.72%  0.44%
for M(+15.99), 1.14%  0.12% for M(+31.99), 0.21%  0.18% for C(+15.99), 4.45%  0.73% for
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C(+31.99), and 1.40%  0.28% for C(+47.98). The overall label efficiency is 33.73%  0.33% at
peptide level, and 58.88%  4.05% at protein level. In comparison, published data17 using the
SPROX approach has a label efficiency of 73.90%  1.91% for M(+15.99), 7.91% 0.55% for
M(+31.99) ,0.17% 0.04% for C(+15.99), 4.10%  1.45% for C(+31.99), 13.69%  0.97% for
C(+47.98). The overall label efficiency is 54.68%  0.65% at peptide level, and 77.51%  1.50%
at protein level. In short, published SPROX approach has better efficiency in modifying
methionine, but IPSA provides more breadth across each protein sequence.

(Figure 2A,

Supporting Data 1)
Since molecular iodine is a strong oxidant, we tested if iodine incubation damages the
protein before digestion by looking at peptide cleavage patterns in samples with and without iodine
labeling. In serum that does not undergo iodine labeling, 69.86  3.22% of peptides have trypsinspecific digestion patterns, 29.60  3.13% were semi-specific, and 0.54 % had unspecific
patterns. On the other hand, for serum that is treated with iodine, 74.95  3.07% of peptide had
specific digestion patterns, 24.60  2.82% has semi-specific digestion, and 0.46  0.30% has
unspecific digestion. The result suggests no backbone cleavage due to iodine.
In sum, SPROX would be preferred when methionine is available in the protein sequence
for its robust label efficiency. IPSA and SPROX are comparable in terms of peptide (Figure 2B)
and protein (Figure 2C) fitting efficiency. However, IPSA would be more ideal for proteins that
have no methionine in the MS detectable region and for quantifying the PFS changes in multiple
domains within the same proteins. We found 74% of proteins had 2 or more sites measured in
IPSA, while in SPROX, 57% of proteins have only 1 site measured (Figure 2C, Supporting
Data1).
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4.5.2 Reproducibility
4.5.2.1 C1/2 variation between analytical approaches
For the replicate serum QTOF-LFQ runs, the shared site distributions of the individual runs
were highly reproducible with a p-value of 0.7922 using a Kruskal-Wallis test (Figure 3A).
Similarly, for the Orbi-TMT runs, individual runs were not significantly different (p-value of
0.8003, Figure 3B). However, Orbi-LFQ does show a significant difference between runs (pvalue=0.0375). There is a distinct bimodal distribution, unlike any of our other runs. (Figure
3C). We similarly compared reproducibility between instruments and acquisition methods.
Comparing the share site distribution of C½ values found in each run, differences between methods
were found to be statistically insignificant with a p-value of 0.1949 (Figure 3D). The average
standard deviation of C½ values for shared sites was 0.27M GdmCl (n=21, Figure3E). Such
findings suggest that results from IPSA QTOF-LFQ and Orbi-TMT runs are the most comparable
and that Orbi-LFQ runs may also be compared with a greater degree of expected variation.

4.5.2.2 Slope direction between analytical approaches
Comparing the technical replicates for QTOF-LFQ, Orbi-TMT, and Orbi-LFQ, we
measured the reproducibility of the denaturation curve’s slope direction (Figure 1C) of the C 1/2
sites that are shared between replications and samples. We found that slope direction is highly
reproducible from run to run in all methods. We compared the percentages of agreeing and
disagreeing curve signs between the 3 technical replicates in cases where a given site was found
in only 2 runs or was found in all 3 runs. Comparing run to run reproducibility between methods,
we found that QTOF-LFQ is the most reproducible followed by Orbi-TMT and then Orbi-LFQ
with total agreement levels being respectively 99.45%, 95.52%, and 94.18% (Figure 3F).
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Figure 3-Reproducibility
Shows Kruskal-Wallis test result for the C1/2 distribution of sites sharing between each technical
replication of serum QTOF-LFQ (A), serum Orbi-TMT(B), and serum Orbi-LFQ (C). The C1/2
distribution of sites sharing between three different serum experiment: QTOF-LFQ, Orbi-TMT,
and Orbi-LFQ is shown in (D). For panel A to D, the n value is 87, 17,46, and 20 respectively.
The n value is the share sites between each technical replication. Detail Kruskal-Wallis test result
can be found in supporting data 2. The red star represents p-value<0.05 in (D). (E) A venn
diagram of The C1/2 the variation (M) between the share sites of different serum experiment. (F)
The percentage of slope agreement of each experiment conditions. ApoTF vs Holo TF and SPROX
condition are discussed in the Denaturation slope as a metric of surface exposure section. n value
of each experiment is the number of the sites that are shared in at least two technical replicates,
where QToF=189,TMT=67, Orbi=181, ApovsHolo=12, SPROX=1223.
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Although the total number of methionine sites in the serum and purified protein data is
much lower than the number of methionine sites available in the published cell homogenate data,
we found the methionine slope was overwhelmingly positive in keeping with the hydrophobicity
index of 1.933 (see discussion below)
Given our findings regarding QTOF-LFQ, Orbi-TMT, and Orbi-LFQ, we can confidently
state that QTOF-LFQ and Orbi-TMT outputs can readily be compared. Hence, in further
discussion, greater focus will be put on our findings from QTOF-LFQ and Orbi-TMT runs. There
is likely room for improvement in the Orbi-LFQ method that could potentially remedy its
decreased reproducibility.

4.5.3 Denaturation Slope As A Metric Of Surface Exposure
The fundamental theory behind SPROX and IPSA is that the surface exposure of the amino
acids when the protein is unfolded increases reactivity. Therefore, the signal intensity of modified
peptides can serve as the reporter for the protein’s denaturation in that region of the sequence.
Amino acids that are buried in the core of protein would become more and more surface accessible
as the protein unfolds. Hence, for an amino acid that is buried in the core, we expect to see a
positive transition: the signal intensity for the modified peptide is low when the protein is in its
native folded state, and the signal increases as the protein unfolds. We found our data (labeling
sites after data filtration, which assure the quality of the regression) are made up of both positive
(positive slope) and negative (negative slope) transitions (Figure 1C). We hypothesize such
differences are a reflection of protein structure. Amino acids that are closer to the surface would
have higher reactivity when the protein is folded, however, the signal decreased when it is unfolded
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because of the formation of new secondary structures or competition for iodine from other
previously buried amino acids.

4.5.3.1 Slope direction is reproducible
Comparing each of the replicates for purified protein and serum, we calculated the
percentages of sites where the slope had the same sign in 2 of 3 replicates. We found that the slope
direction was highly reproducible from run to run, with total agreement levels being 99.45% for
serum (Figure 3F). In the purified protein we found that 10 of 12 shared sites had the same slope
direction (83.33%) (Figure 3F). The reproducibility of slope direction between runs and across
conditions implies that slope direction may have significant implications in describing protein
structure and unfolding. We found that SPROX has a total agreement level for slope direction at
74.24%, which suggests that slope is similarly reproducible for both IPSA and SPROX 17 and may
be intrinsic to the protein structure.

4.5.3.2 Slope direction vs Amino Acid /Label type
We then examined trends in the C1/2 value and slope direction of the sigmoid curve in
reference to amino acid residue identity and label type for peptides from serum runs. Assuming a
stepwise reaction mechanism for both IPSA and SPROX mediated labeling multiple products are
possible (Figure 1B). In term of slope direction, mono iodinated histidine (H(+125.90)), tended
to have negative slope (Poisson test, p<0.0001). Di-iodinated histidine (H(+251.79)), however,
tends to have more positive slope (Poisson test, p=0.0385); Mono and di-iodinated tyrosine species
(Y(+125.90) and Y(+251.79)) tended to have positive slope (Poisson test, p<0.0001, p<0.0001);
Oxidized methionine (M(+15.99)) appeared to have a trend towards positive slope, but such a trend
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lacked statistical significance (Poisson test, p=0.0710); Cysteine, probed in its sulfinated form
(C(+31.99)), tended to have positive slope (Poisson test, p=0.0089); Other probed amino acid and
label types showed no statistically significant trend in slope direction. (Figure 4A, Supporting
Data 2). Similarly, we checked the slope tendency for SPROX data17: mono-oxidized methionine
residues (M(+15.99)) overwhelmingly tended to have positive slope (p<0.0001), di-oxidized
methionine residues (M(+31.99)) tended to have negative slope (p=0.0333). Cysteine, probed in
its sulfinated form (C(+31.99)), tended to have negative slope (p<0.0001), and its sulfonated form
(C(+47.98)), tend to have positive slope (p=0.0015) (Figure 4A, Supporting Data 2). The slope
tendency of both forms of methionine are the small between IPSA and SPROX. We again confirm
the observation that slope is not unique to IPSA but universal among similar chemistry
denaturation approaches.

4.5.3.3. Slope direction vs SASA
We tested whether amino acid hydrophobicity correlated with slope direction.
Hydrophobicity decreases from C, M, Y, to H with a hydropathy index 2.5, 1.9, -1.3, and -3.2
respectively33. There was a pronounced trend of increased frequency of negative slopes for H
relative to C (Figure 4A). Because hydrophobicity influences the surface accessibility in folded
structures, we tested the hypothesis that the slope direction is correlated to whether an amino acid
is buried in the core of the protein. To do this we calculated the solvent accessible surface area
(SASA) value of proteins observed in our serum run from published X-Ray Crystallography
structures using Pyrosetta25. In our serum data, 37 proteins with 202 sites have corresponding xray crystallography data available. For these comparisons, we avoided structures containing drugs
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Figure 4-Anslysis of Slope direction
(A) The slope tendency for each IPSA (top 5 bars) and SPROX (bottom 4 bars) label type that had
at least 10 measurements. (B) The serum site solvent accessible surface area (SASA) distribution
per positive (blue) and negative (orange) slope group (C-E) The serum site solvent accessible
surface area (SASA) distribution of Y, M, C comparing to H. (F) The serum site C1/2 distribution
per positive (blue) and negative (orange) slope group (G-I) The serum site solvent accessible
surface area (SASA) distribution of Y, M, C comparing to H. The red star represents p-value<0.05.
Refer to Supporting data 2 for Kruskal-Wallis test result detail.

or non-native protein complexes. For a comprehensive list of selected structures see Supporting
Data 334-70. We found that SASA values were significantly different between label sites that have
positive and negative slope in serum. (Figure 4B). The mean SASA value for C, M, Y, and H are
12.6613.40, 27.5127.64, 30.1132.63, and 74.5543.44, respectively (Supporting Data 2). Of
those, histidine residues, which exhibit both negative slope and positive slope, had significantly
higher SASA values than the other residues, Y, C, and M, that have mostly positive slope (KruskalWallis test , p value all <0.0001) (Figure 4C-E). The standard deviation for these SASA values
is a reflection of the diversity of structures, not error in the calculation. The C½ values were
significantly different for label sites that have positive and negative slope in serum (Figure 4F).
Histidine residues’ average C1/2 value 1.45  0.76, were significantly lower than other residues, Y
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(1.83  0.68), M (1.92  0.84), and C (2.02  0.61), and (p=0.0006, 0.0259, 0.0078 respectively)
(Figure 4G-I, Supporting Data 2). These findings are largely consistent with the hypothesis that,
as the concentration of GdmCl increases and the protein unfolds, formerly buried, hydrophobic
residues are exposed to iodine labeling resulting in an increase in abundance of labeled
hydrophobic species, hence yielding positive slope. Conversely, as more residues are exposed to
iodine labeling, iodinated hydrophilic species see a decrease in abundance due to formation of new
secondary structure or increased competition for access to iodine71.

4.5.4 C1/2 For Transferrin And Other Serum Proteins
4.5.4.1 Reproducible C1/2 measurements in the context of the serum proteome
Three technical replicates of serum from a healthy human subject were combined to
generate one regression curve. We measured C1/2 for 283 sites across 57 serum proteins after data
filtration. Of those, 18 proteins measured at 1 site, 24 proteins measured at between 2 and 5 sites,
9 proteins between 6 and 10 sites, and 6 proteins >10 sites. Of the proteins that have at least two
C1/2 sites measured, the average C1/2 shows a normal distribution, with 72% of the proteins having
an average C1/2 in between 1M and 2M (Supporting Figure 5A). Supporting Data 4 lists the
number of C1/2 sites measured, average C1/2, C1/2 standard deviation, C1/2 relative standard
deviation, length, mass, concentration and rank abundance from literature72 for each of the 39
proteins. Human serum albumin (HSA), the most abundant serum protein, has a high average C1/2
at 1.96  0.55M. Using the DAVID Bioinformatics Resource73,

74

, the ontology cluster of

complement and coagulation cascades (n=7), immunoglobulin-like domain (n=10), and transport
(n=10) have C1/2 mean 1.78  0.05M, 1.63  0.25M, and 1.60 1.33M (Figure 5B). However, the
comparison of protein level PFS is far less useful than the comparison of sites within proteins.
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Figure 5-Average C1/2 Of Serum Proteins
(A) The average C1/2 distribution of 39 proteins that has at least 2 C1/2 sites measured. (B) Box
plot of the C1/2 per ontology cluster analysis.

4.5.4.2 Transferrin (TF) structural stability changes with binding of iron:
The analysis on human transferrin (TF) demonstrated the sensitivity of IPSA in measuring
C1/2 changes between different conditions, and across the protein sequence. TF is a good candidate
for this proof of principle analysis for two reasons. First, TF is one of the abundant serum proteins
and has 698 residues divided into two major domains connected by a short loop. We had good
peptide coverage of the entire protein even in the presence of HSA. Second, TF has two distinct
forms differentiated by substrate (iron) binding. TF is the primary transport protein for non-heme
iron in blood serum. The N-terminal domain includes amino acids 20-347, and the C-terminal
domain includes amino acids 361-698. Each domain has an iron binding site which have slightly
different iron binding affinities75, 76. The iron-binding site in the N-terminal domain is comprised
of D82, Y114, Y207, and H26877, and the C-terminal binding site is comprised of D411, Y445,
Y536, H60477 (Figure 6A). The holo form of transferrin has Fe3+ bound in both domains and apo
from has both domains empty. It has previously been shown that the folding stability of the iron
binding sites decreases when the lobes open, and the iron is released78, and the transferrin
saturation for a healthy individual is between 20-45%79. Thus we expect that the C1/2 is lowest in
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apoTF, highest in holoTF, and the C1/2 of serum TF should be somewhere in between apoTF and
holoTF.
To better assess the PFS of TF in serum as a reflection of iron-binding status, we
established the baseline by subjecting purified apoTF and purified holoTF to IPSA. There were
17 site-specific C1/2 values measured in serum TF, 32 in Apo TF, and 26 in holoTF. Acquiring
the C1/2 of the same site across conditions is one of the challenges in the current IPSA workflow,
primarily because of the shotgun proteomics approach. We measured C1/2 values for 6 out of the
8 iron binding sites on TF. We were able to measure C1/2 for 3 of the amino acids which directly
chelate the iron (Y114, H268, and H604). Poor signal to noise for these amino acids resulted in
missing values in some of the conditions, thus these could not be used for comparison. We were
able to monitor PFS of Y115, the residue immediately adjacent to the iron binding site Y114 in
both apoTF and holoTF. We found it was significantly higher in holoTF than in apoTF.
(Figure6B, Figure7). It suggests the environment close to the binding site has lower C1/2, thus is
less stable when there is no iron bound (apoTF); and has higher C1/2, thus is more stable when
both iron binding sites are occupied (holoTF). Such observation agrees with the expectation that
apoTF is less stable than holoTF78 , and further confirms that IPSA has the sensitivity to quantify
the PFS difference between protein states.
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Figure 6-Site C1/2 of Transferrin
(A)The crystal structure of transferrin (4X1B70). N-domain residue 20-180 are in cornflower blue
,and 181-348 are in light sea green. C-domain residue 362- 529 are in pink, 530-699 are in
orange, and the connecting loop 349-361 is in gray . The iron biding site are in purple with the
amino acid side chain turned on. The number label pointed to the amino acid with side chain
turned on highlights the structure location of each of C1/2 site shown in panel B. The residue
number used here is from uniport ID. (B)Show the site C1/2 measured from N’ to C’ of transferrin.
C1/2 sites that are share in at least 2 of the experiments (ApoTF, HoloTF, and serum ) are shown
on the plot. The error bars show the confident interval at 95% of the site C1/2, after fitting all
data point that cover the same site. (C) The share site C1/2 distribution of transferrin from apoTF
and holo TF experiment. (D) The share site C1/2 variation of transferrin between each of the serum
technical replantation and between ApoTF and Holo TF experiment.
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Figure 7-Denaturation curve for Transferrin Y115 (+125.90)
The graphic output from CHalf of the peptides that are used to compute site C1/2 value for Y115
(+125.90). The plots show the normalized peptide area for all 3 replications and the denature
curve. (A) peptide from ApoTF experiment. (B-E) four peptides from Holo TF experiment.
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Comparing changes in site specific C1/2 across the conditions showed that apo TF sites are
generally lower than holo TF, and serum TF is slightly below holo TF. (Figure 6B, supporting
data 4). The shared site C1/2 was statistically significant between Apo and Holo (1.60  0.70M
and 1.95 0.77 M respectively, p=0.0056, Figure 6C). Serum TF has an average C1/2 of 1.72 
0.78M, which is slightly higher than apo (supporting data 2). The PFS of serum TF seems to
imply that as soon as one of the TF iron binding sites is occupied, the overall protein structure is
stabilized. It has been previously observed that the two iron binding sites are not identical and have
different affinities78. Note that the observed sites are observed less frequently in C-terminal domain
than in N-terminal domain across 3 conditions. It is likely that there are other factors affecting the
efficiency of the modification of the reporter amino acids
Comparing replicate C1/2 values for shared sites in purified protein versus the serum, we
found that variation between serum replicates was significantly lower than variation between Apo
and Holo (p=0.004) with median standard deviations of 0.1276M and 0.3406M for serum
replicates and apo/holo respectively (Figure 6D). We also noticed that some regions of the protein
had higher variability (Y64, Y242, H308, Y593) than the other, which may indicate
conformational flexibility or multiprotein complex formation which creates multiple
conformations at these sites. Based on these findings, we suggest that IPSA can measure
meaningful differences in PFS between different conditions and also that individual sites in the
protein report independent values for conformational change.

4.5.5 X-ray Crystallography suggests in vivo structural ensembles for TF
To test whether variation in folded structures might explain higher variation in C1/2 values
of some protein domains, we compared the variability in known structures for TF. At the time of
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publication there were 17 published TF structures55, 69, 70, 77, 80-88 that are full-length, have resolution
<3 Å, without extra ligands or binding partners.
To quantify the variation between x-ray crystal structures, we calculated the relative
standard deviation (RSD) for each of the structural parameters (SASA, b-factor and REU). The
RSD range highlights TF regions where SASA (15 to 183%), b-factor (18 to 59%), and REU (74%
to 7841%) changed between structures (Figure 8, Supporting Data 5) This variation in the crystal
structure may replicate some of the in vivo structural dynamics and highlights variability which
may affect C1/2 values. For Transferrin the population of in vivo structures may be influenced
primarily by iron concentration, but the variation profile of each parameter (SASA, b-factor, RUE,
and C1/2) between the crystal structures was unique. REU has significant variation around residues
200, 320, and 670.
On the other hand, the linear regression doesn’t show significant correlation between the
C1/2 RSD and the RSD of SASA, b-factor and REU, which suggests that there are other factors
that take place in order to model the correlation. Low correlation with C1/2 values versus the
calculated SASA/b-factor/REU for the rest of the serum proteins (Figure 9, Supporting Data 3)
may reflect that the environment during crystallization didn’t contain the milieu of small molecule
and protein binding partners available in the serum.
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Figure 8-Variation Between Transferrin Crystal Structures
The SASA, b-factor and REU are extracted from 17 TF structures (Supporting Data 5) that are
full-length, have resolution <3 Å and with varies ligand and binding partners and calculated the
moving average (10 residues) of relative standard deviation (RSD) for each of the structural
parameters. The RSD of each structural parameters are plug against the TF uniport residue
number from N’ to C’ to observe the variation at along the sequence. (A) SASA RSD (B) b-factor
RSD, and (C) REU RSD. (D) Shows the C1/2 RSD of 18 TF sites that are observed in at least 2 of
the experiment conditions (ApoTF, HoloTF, and serum) to indicate the PFS variation observed
between different iron binding state. The blue shade cover the N’-domain, the pink shade covers
the C’-domain, and the white shade covers the linker loop between two domains. The red
straight line in highlight Y115, the site right next to one of the iron binding site and its C1/2 was
measured in Apo TF, and Holo TF.
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Figure 9- Structural Parameter vs C1/2 for serum proteins
High quality X-Ray Crystallography structures have traditionally been used to estimate protein
stability using solvent accessible surface area (SASA), Rosetta energy units (REU), b-factor, and
secondary structure (SS). As both C1/2 values and the slope direction of denaturation curve are
components of in situ PFS, we compared serum protein site specific C1/2 values generally, or
subsets with different slope direction (positive/negative) to SASA, REU, b-factor and SS of 37
proteins/202 sites in serum. 37 proteins/202 sites’ structural parameter: Solvent Accessible
surface area (SASA), b-factor, Rosetta energy unit (REU), and secondary structure designation
(SS) are extracted from its corresponding crystal structure (Supporting Data 3) and used to
compare with C1/2 value. The Spearman Correlation test and Robust linear model for correlation
test for SASA, b-factor, and REU, where structural parameters as dependent variable (y-axis), and
C1/2 value as independent variable (y-axis). The red star represents pvalue<0.05. Refer to
Supporting Data 2 for detail spearman correlation and Kruskal-Wallis test result
(A-C) SASA vs C1/2. (A) shows overall correlation, (B) shows the correlation for the sites
that have positive slope, and (C) show the correlation for the sites that have negative slope. The
SASA value indicates how buried of a given amino acid (AA). The SASA value for a completely
buried AA is 0, and a higher SASA value indicate the AA is more surface accessible. We found a
negative correlation of -0.2197 between overall C1/2 and SASA values with a p-value of 0.0017 and
a linear model, y=−10.8449 x+51.7569, with a slope p-value of 3.55E-4. In sum, we found a weak
negative correlation between C1/2 and SASA, suggesting that solvent inaccessible sites are more
stable and require higher guanidine concentrations to unfold. Such correlation is insignificant for
the other subsets.
(C-F) b-factor vs C1/2. (D) shows the overall correlation, (E) shows the correlation for the
sites that have positive slope, and (F) show the correlation for the sites that have negative slope.
b-factor is an experimental value in protein crystallography that indicates mobility and dynamics
of individual atoms or sidechains. A large b-factor reflects higher flexibility of the atoms and
sidechains32. We expect a negative correlation, as the higher flexibility make the protein less stable
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and shall give a lower C1/2 value. We found a negative correlation of -0.1636 for overall C1/2 with
a p-value 0.0200 as expected and a linear model, y=-7.2945x+ 63.5109, with a slope p-value of
1.76E-2. suggesting as the higher flexibility region is less stable and require lower guanidine
concentrations to unfold . Such correlation is insignificant for the other subsets.
(G-I) b-factor vs C1/2. (G) shows the overall correlation, (I) shows the correlation for the
sites that have positive slope, and (H) show the correlation for the sites that have negative slope.
The REU scale quantifies the quality and stability of the structure. Lower REU indicates a better
or more stable structure31. We expected to see a negative correlation, as a lower REU values imply
the site is more stable and may have a higher C1/2 value. We likewise compared C1/2 values to REU
values using a Spearman Correlation test and robust regression model. We found no significant
correlations between overall C1/2 and REU values and other subsets, except for negative slope.
For negative slope, we found a positive correlation of 0.3808 between C1/2 and REU values with a
p-value p=0.0016 for negative slope subset, and a linear model, y=2.1848x−0.7647, with a slope
p-value of 1.90E-3. The unexpected finding is possibly due to the fact that REU function used for
different x-ray crystallography is different, thus make it harder to compare REU between different
protocol31. Further investigation should segregate the protocol to find the real correlation between
C1/2 value and REU.
(J-L) SS vs C1/2. (J) shows the overall distribution, (K) shows the distribution for the sites
that have positive slope, and (L) show the distribution for the sites that have negative slope. There
are three categories of secondary structure extracted from PDB, helix (H), beta-sheet (E), and
loop (L). The secondary structure is classified using DSSP algorithm26. Using Kruskal-Wallis
tests, we compared distributions of C½ values for sites grouped by their secondary structures
(H,E,L). Since beta-sheet is prone to form aggregate and fibril, we expect to see it is more stable
We found beta-sheet has higher mean than helix and loop in overall and positive slope subset, but
the mean of beta-sheet is lower than helix and loop in negative slope subset. However, the
differences are only significant for negative subset with a p-value 0.0318, not for other subsets.
We had learned that AA that are more surface like histidine tend to have more negative slope
denaturation curve. The significant lower C1/2 found in negative subset for beta-sheet help form
a hypothesis of aggregation formation that worth further exploration: surface exposed beta-sheet
is less stable and have higher tendency to be unfold, and those surface exposed unfolded betasheet is prone to aggregate with other unfolded beta-sheet.
We hypothesis the weak correlation C1/2 and structural parameters is due to the structural
variation between the experimental differences of each crystal structures in the dataset. While the
C1/2 values are from a in situ environment, the corresponded structural parameters are from one
of the many published crystal structures of that protein, which is formed in an ex vivo environment.

4.6 Discussion
Poor control of protein homeostasis across the proteome is a critical precursor to many of
today’s untreatable diseases2. A common observation among these diseases and even aging is that
protein aggregates have formed89. To address the etiology of these diseases, an in vivo metric of
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folding quality is necessary. The goal of this study is to introduce new tools for researchers to
study protein folding stability across the proteome in situ. The iodine protein stability assay
(IPSA) modifies H, Y, M, and, C providing higher resolution across the protein sequence, which
monitors PFS changes in subdomains, ligand binding, or protein-protein interaction. It utilizes a
chemical denaturation approach which is effective in human serum, facilitating human studies.
The covalent modification introduced by iodine is irreversible and allows downstream
fractionation or enrichment to broaden coverage. IPSA provides increased granularity to track a
change in a protein’s denaturation midpoint (C1/2, which is proportional to Gunfolding) along the
protein sequence in different conditions. The CHALF data processing tool provides a user-friendly
tool to calculate denaturation midpoint for both chemical (SPROX, IPSA) and thermal (TPP, LiP)
data, with easily modifiable settings.
The fundamental principle behind IPSA builds on the idea of protein footprinting, which
is monitoring the change in a protein’s surface accessibility in different conditions 9,

90

.

Traditionally, the chemical denaturation method for protein folding stability targets the
hydrophobic amino acids, like methionine, because these tends to be at the core of the protein. We
observed that in addition to the C1/2, the denaturation curve slope direction is biased by the surface
accessibility of the amino acid. The inclusion of slope direction opens up the possibility for using
any amino acid as reporters, as long as the modification is irreversible and the reaction efficiency
is reasonable. In that line of thinking, the Fast Photochemical Oxidation of Proteins (FPOP), would
make a good candidate to study protein denaturation and protein folding stability because of its
high reaction efficiency and the greater coverage (modifying 19 out of the 20 amino acids) 91.
However, the excimer laser required for FPOP is not available in most laboratories. The IPSA
method uses common reagents and is reproducible in complex matrices like human serum, where
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we measure 283 sites across 57 proteins. To our knowledge this is the first time the PFS
information for human serum proteins is measured in the context of the blood serum (in situ). The
work in this study creates a reference point for researchers that have interest in the quality metrics
of human serum proteome change with time, diet, or other variables. Using Transferrin as a model,
we were able to confirm that IPSA can measure the significant difference in stability between
conditions (apoTF and holoTF) in agreement with the literature expectation. In addition, we also
observe that the C-terminal domain in TF reacts differently to iodine treatment, which suggests a
difference in functionality. This concurs with the literature that C-terminus of TF has an effect on
iron release92-94.
The structure of a protein is critical to its function, especially in ligand binding and proteinprotein interactions. While maintaining certain stability is important for protein integrity, structural
flexibility is a critical part of how proteins do their jobs. In our attempt to link C 1/2 and structural
parameters (SASA, b-factor, and REU) from x-ray crystal structures, we found only weak
correlations. At the same time, we observed that there is significant variation of these structure
parameters between different crystal structures even without protein binding partners or ligands.
The variation between structures suggests the weak correlation between C1/2 and structural
parameters may be due to structural ensemble differences between experimental conditions. This
illustrates the fact that while x-ray crystal structure are remarkably valuable in understanding
protein structure and function, it is important to combine other in vivo measurements to access in
vivo structural changes relevant to disease conditions or drug binding states. Techniques like IPSA
may allow us to assess the dynamics of protein structure in different conditions and biological
contexts.
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Similar to the results shown here, SPROX has been shown previously to detect structural
changes due to ligand binding17, 95, 96. The increased number of reporters provided by IPSA
increases the ability to monitor drug binding to proteins. This increases the potential to use protein
folding stability (PFS) in drug development and potentially for diagnosis10. This is valuable
because PFS quantifies protein folding stability, which makes it perfectly suitable to study diseases
of protein aggregation, like Alzheimer’s or cardiac amyloidosis. Finally, PFS in combination with
the kinetics of protein synthesis (turnover rate, synthesis rate, and degradation rate) can help better
describe the mechanism of the loss proteostasis, which is one of the primary reasons for aging and
age-related diseases. All these IPSA applications provide orthogonal information to current
concentration focused studies.
To accomplish these potential applications, the most urgent next step is to create assays
which measure C1/2 for the same site consistently across different conditions to facilitate
comparisons. This may be addressed by using different MS acquisition methods, such as targeted
MS, DIA, or real-time search, to measure iodinated peptides repeatedly and reliably. Despite this
hurdle, the current IPSA study supports the potential for more applications.
In summary, we have demonstrated that IPSA gives reproducible measurements of
biologically relevant differences in protein folding stability and has high resolution to track
stability differences within the protein. This study also provides an initial census of C1/2 for proteins
in undepleted human serum, which lays foundation for future study.
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4.7 Supporting Information
The following supporting information will be available on the journal website once published
and is available at https://scholarsarchive.byu.edu/data/42 .
Supporting Data 1(xlsx)- IPSA and SPROX’s label and fitting efficiency
Supporting Data 2(xlsx)- Statistics test results for reproducibility, slope tendency, C1/2 and SASA
distribution, and C1/2’s correlation to structural parameter.
Supporting Data 3 (xlsx)-C1/2 value and structural parameters for each site measured
Supporting Data 4 (xlsx)-Merged CHalf output (combined label site) and the average C1/2 for
serum protein
Supporting Data 5 (xlsx)- Structural parameters of 17 different transferrin structures
Supporting Information (docx)-MS Specture For Each Label Type
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4.9 Abbreviation
apoTF - Apo Transferrin
C1/2 - Denature Midpoint
CD - Circular Dichroism Spectroscopy
DSSP - Dictionary Of Secondary Structure Of Proteins
GdmCl- Guanidinium chloride
holoTF - Holo Transferrin
HSA - Serum Albumin
IPSA - Iodination Protein Stability Assay
LCMS- Liquid Chromatography–Mass Spectrometry
LiP - Limited Proteolysis
MS - Mass Spectrometry
Orbi-LFQ – Orbitrap Mass Spectrometer In Label Free Comparison
Orbi-TMT – Orbitrap Mass Spectrometer In Tandem Mass Tag Comparison
PFS - Protein Folding Stability
PTM-Post Translation Modification
QTOF-LFQ – Quadropole Time Of Flight Mass Spectrometer In Label Free Comparison
REU - Rosetta Energy Unit
SASA - Solvent Accessible Surface Area
SPROX - Stability Of Proteins From Rates Of Oxidation
SS - Secondary Structure
TMT- Tandem Mass Tag
TPP - Thermal Proteome Profiling
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CHAPTER 5: CONCLUSION

Anyone who is fascinated with what living organisms can do should also be fascinated
with the complexity of protein networking, for proteins are the primary players making all the
magic. To sustain life, not only individual protein need to function accurately: at the right time, in
the right place, with the correct concentration, and have the right shape, but all the proteins in the
proteome need to function accurately, more importantly, interact accurately. When the proteins are
in functional balance, the protein homeostasis is maintained, the living organism is young and
healthy. In contrast, when protein homeostasis is lost, the living organism starts to age and
develops diseases. Human has a much longer life span nowadays, but at the same time, more agerelated diseases negatively impact the quality of life of the elderly. It is the mission of scientists in
our generation to find the keys to improving life quality late in our lives. I believe the key is
studying the mechanism of protein homeostasis using mass spectrometry.
Homeostasis is not a foreign term to anyone. We have been taught that we need to have a
balanced life: work-life balance, nutrition balance, financial balance, and the list continues. The
quality of our life is determined by how balanced we are. I was raised by a physician of Tradition
Chinese Medicine who treats her patients based on the concept of homeostasis and holistic. She
always tells me that the key to treating a disease is to recognize what is lacking in a patient’s whole
body, not just one single organ or symptom, and supply what is short, and vice versa, knowing
what exceeds and eliminates the extra. Thus, even with the same disease, the treatment might be
very different from one person to another one. She was able to treat patients with terminal cancer.
Those patients turned to my mother because their doctors had declared that there was nothing more
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they could provide. The younger me wondered, where is the gap between traditional Chinese
medicine and modern medicine?
I remember the first time I learned about protein homeostasis was during the poster section
of BYU’s graduate student recruiting event. Dr. Price introduced the kinetic model of protein
homeostasis. At the time, there was only the quantity aspect in the model. I was fascinated. The
older me thought that was probably where I could start to bridge the gap between traditional
Chinese medicine and modern medicine. If I can explain protein homeostasis, I may better explain
traditional Chinese medicine’s homeostasis. I was blessed that Dr. Price took me into his lab, and
since then, I have based all my Ph.D. research on adding quality to the protein homeostasis model.
We have come up with a general protein homeostasis model that included both quantity and quality
aspects (Chapter 1); tailored that model to transthyretin to understand the mechanism behind
cardiac amyloidosis (Chapter 2); found structure differences of human serum albumin between
patients with and without rheumatoid arthritis (Chapter 3); and developed a better assay, IPSA
(Chapter 4), that can be used on human serum and can track the quality change within individual
proteins.
Now we have a completed model and the techniques to take measurements, and we can
finally start applying this model and describing disease mechanisms. We have recently started a
human study that includes 150 subjects with three different transthyretin mutation statuses. In the
study, we will apply IPSA to the serum and measure the protein folding stability of proteins in the
serum proteome. The goal is to learn how the protein folding stability of transthyretin, and also
other proteins, are different between mutation status, and hoping to get ideas for earlier diagnosis.
Later we will treat human subjects with deuterium water to acquire protein concentration and
turnover rate. Combining concentration, turnover rate, and protein folding stability, we can then
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use the protein homeostasis model to describe the mechanism behind cardiac amyloidosis. We will
also apply the protein homeostasis model to the APOE mice to study the mechanism of
Alzheimer’s disease. Of course, method optimization never ends. There will be continued efforts
put in to increase assay efficiency at all levels: chemical reaction, assay automation, and LC/MS
detection.
At the conclusion of this dissertation, I want to reinforce two ideas: holistic and protein
homeostasis. The scientific community has developed amazing treatments for many diseases
because of our increased understanding of a particular protein signaling pathway. However, in
most cases, we are satisfied with 50% efficacy. As more we learned about the complexity of protein
networking, we started to realize that different pathways contribute to the same disease. That is
when personalized medication came in. We can now prescribe specific treatments, e.g., breast
cancer has different treatments targeting different oncogene proteins. That is the importance of
having a holistic view of diseases.
On the other hand, protein homeostasis includes both quantity and quality aspects. The
quality aspect has long been neglected, mostly because of technical challenges. There were no
convenient tools to study in vivo protein quality (protein structure, protein folding stability).
Thanks to the advancement and increased availability of mass spectrometry, we can now identify
thousands of proteins in a single experiment with the cellular context retained. It makes it possible
to study protein networking holistically. More importantly, with more robust assays made
available, like IPSA, it is now possible to quantify protein quality in vivo. It is my hope to see
there will be more studies in the future that combine both quantity and quality aspects of protein,
and holistically describe protein homeostasis of disease mechanisms.
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